[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 205
1. Shin HR, Oh JK, Lim MK, Shin A, Kong HJ, Jung KW, Won YJ, Park S, Park SJ, Hong ST: Descriptive epidemiology of cholangiocarcinoma and clonorchiasis in Korea. J Korean Med Sci; 2010 Jul;25(7):1011-6
MedlinePlus Health Information. consumer health - Bile Duct Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Descriptive epidemiology of cholangiocarcinoma and clonorchiasis in Korea.
  • In 2009, infection with the liver fluke Clonorchis sinensis (C. sinensis) was classified as "carcinogenic to humans" (Group 1) based on its involvement in the etiology of cholangiocarcinoma by the International Agency for Research on Cancer.
  • However, little is known about the descriptive epidemiology of cholangiocarcinoma in Korea.
  • Cholangiocarcinoma incidence rates are currently rising, even while primary liver cancer incidence rates are decreasing.
  • Annual percent changes in cholangiocarcinoma incidence rates were 8% for males and 11% in females.
  • Known areas of C. sinensis endemicity showed high incidence rates of cholangiocarcinoma.
  • From a meta-analysis, the summary odds ratio for cholangiocarcinoma due to C. sinensis infection was 4.7 (95% confidence interval: 2.2-9.8).
  • [MeSH-major] Bile Duct Neoplasms / epidemiology. Bile Ducts, Intrahepatic / pathology. Cholangiocarcinoma / epidemiology. Clonorchiasis / epidemiology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Animals. Female. Humans. Korea / epidemiology. Male. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Gastroenterol Hepatol. 2002 Oct;17(10):1049-55 [12201863.001]
  • [Cites] Lancet Oncol. 2009 Apr;10(4):321-2 [19350698.001]
  • [Cites] Acta Trop. 2003 Nov;88(3):177-86 [14611872.001]
  • [Cites] World J Surg. 1995 Jul-Aug;19(4):637-41 [7676713.001]
  • [Cites] Int J Epidemiol. 1996 Oct;25(5):933-40 [8921477.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 1999;6(2):136-41 [10398900.001]
  • [Cites] N Engl J Med. 1999 Oct 28;341(18):1368-78 [10536130.001]
  • [Cites] Lancet Infect Dis. 2005 Jan;5(1):31-41 [15620559.001]
  • [Cites] J Helminthol. 2005 Sep;79(3):269-81 [16153321.001]
  • [Cites] J Hepatol. 2006 Jun;44(6):1066-73 [16480786.001]
  • [Cites] Br J Cancer. 2006 Jun 5;94(11):1751-8 [16736026.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2006 Jun;15(6):1198-203 [16775181.001]
  • [Cites] J Natl Cancer Inst. 2006 Jun 21;98(12):873-5 [16788161.001]
  • [Cites] Am J Trop Med Hyg. 2006 Jul;75(1):93-6 [16837714.001]
  • [Cites] Clin Liver Dis. 2008 Feb;12(1):131-50, ix [18242501.001]
  • [Cites] Am J Gastroenterol. 2008 Jul;103(7):1716-20 [18557716.001]
  • [Cites] Korean J Parasitol. 2009 Mar;47(1):37-47 [19290090.001]
  • [Cites] Hepatogastroenterology. 2003 Jan-Feb;50(49):8-12 [12629979.001]
  • (PMID = 20592891.001).
  • [ISSN] 1598-6357
  • [Journal-full-title] Journal of Korean medical science
  • [ISO-abbreviation] J. Korean Med. Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2890876
  • [Keywords] NOTNLM ; Clonorchis sinensis / Korea / cholangiocarcinoma
  •  go-up   go-down


2. Borie F, Niampa H, Bouvier AM, Faivre J, Launoy G, Delafosse P, Velten M, Buemi A, Peng J, Grosclaude P, Trétarre B: [Current management and prognosis of intrahepatic cholangiocarcinoma in France]. Gastroenterol Clin Biol; 2009 Oct-Nov;33(10-11):971-6
MedlinePlus Health Information. consumer health - Bile Duct Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Current management and prognosis of intrahepatic cholangiocarcinoma in France].
  • INTRODUCTION: Intrahepatic cholangiocarcinoma (ICC) is a rare tumor with a poor prognosis.
  • METHODS: Between 1997 and 1998, 1100 cases of primary liver cancer were observed in nine French departments: 68 were ICC.
  • [MeSH-major] Bile Duct Neoplasms / mortality. Bile Duct Neoplasms / therapy. Bile Ducts, Intrahepatic / pathology. Cholangiocarcinoma / mortality. Cholangiocarcinoma / therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Chemotherapy, Adjuvant. Female. France / epidemiology. Humans. Male. Middle Aged. Neoplasm Metastasis. Prognosis. Radiotherapy, Adjuvant. Registries. Survival Analysis

  • Genetic Alliance. consumer health - Intrahepatic cholangiocarcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19647386.001).
  • [ISSN] 0399-8320
  • [Journal-full-title] Gastroentérologie clinique et biologique
  • [ISO-abbreviation] Gastroenterol. Clin. Biol.
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


3. Ghali P, Marotta PJ, Yoshida EM, Bain VG, Marleau D, Peltekian K, Metrakos P, Deschênes M: Liver transplantation for incidental cholangiocarcinoma: analysis of the Canadian experience. Liver Transpl; 2005 Nov;11(11):1412-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Liver transplantation for incidental cholangiocarcinoma: analysis of the Canadian experience.
  • Cholangiocarcinoma is a biliary tumor, which not infrequently complicates primary sclerosing cholangitis.
  • The goal of this retrospective study was to perform a national review of outcomes after liver transplantation in Canadian recipients found to have incidental cholangiocarcinoma in their explanted native liver.
  • Six of the seven liver transplant centers in Canada provided clinical and follow-up information on all liver transplant recipients found to have incidental cholangiocarcinoma in their explants.
  • The diagnosis or suspicion of cholangiocarcinoma prior to transplantation were exclusion criteria for this study.
  • Ten individuals with cholangiocarcinoma were transplanted between 1996 and 2003.
  • In conclusion, although early survival of patients transplanted for incidental cholangiocarcinoma appears good, intermediate- and long-term survival rates are not better than for individuals historically transplanted with known cholangiocarcinoma.
  • Aggressive investigation for cholangiocarcinoma is mandated.
  • [MeSH-major] Bile Duct Neoplasms / surgery. Bile Ducts, Intrahepatic. Cholangiocarcinoma / surgery. Incidental Findings. Liver Transplantation / methods
  • [MeSH-minor] Adult. Aged. Canada. Female. Follow-Up Studies. Graft Rejection. Graft Survival. Humans. Male. Middle Aged. Postoperative Complications / epidemiology. Probability. Retrospective Studies. Risk Assessment. Survival Analysis

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • MedlinePlus Health Information. consumer health - Liver Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16237695.001).
  • [ISSN] 1527-6465
  • [Journal-full-title] Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society
  • [ISO-abbreviation] Liver Transpl.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


Advertisement
4. Yang WL, Zhang XC, Zhang DW, Tong BF: Diagnosis and surgical treatment of hepatic hilar cholangiocarcinoma. Hepatobiliary Pancreat Dis Int; 2007 Dec;6(6):631-5
MedlinePlus Health Information. consumer health - Bile Duct Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnosis and surgical treatment of hepatic hilar cholangiocarcinoma.
  • BACKGROUND: Hepatic hilar cholangiocarcinoma can be diagnosed early with the progress in diagnostic imaging, and thus the rate of resection of the tumor has increased markedly.
  • To assess the effectiveness of resection, we reviewed 185 cases of hepatic hilar cholangiocarcinoma diagnosed and treated at our hospital.
  • METHODS: The clinical data of 185 patients with hepatic hilar cholangiocarcinoma who had been treated surgically from 1972 to 2006 were retrospectively analyzed.
  • Primary symptoms included upper abdominal discomfort or pain, anorexia, tiredness, weight loss and progressive jaundice.
  • CONCLUSIONS: Once patients are diagnosed with hepatic hilar cholangiocarcinoma, they should undergo exploratory laparotomy.
  • Resection is the most effective method for the treatment of hepatic hilar cholangiocarcinoma.
  • [MeSH-major] Bile Duct Neoplasms / surgery. Bile Ducts, Intrahepatic. Cholangiocarcinoma / surgery
  • [MeSH-minor] Adult. Aged. Cholangiopancreatography, Endoscopic Retrograde. Drainage. Female. Follow-Up Studies. Humans. Male. Middle Aged. Retrospective Studies. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18086631.001).
  • [ISSN] 1499-3872
  • [Journal-full-title] Hepatobiliary & pancreatic diseases international : HBPD INT
  • [ISO-abbreviation] HBPD INT
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  •  go-up   go-down


5. Thomas H, Heaton ND: Late recurrence after surgery for cholangiocarcinoma: implications for follow-up? Hepatobiliary Pancreat Dis Int; 2008 Oct;7(5):544-6
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Late recurrence after surgery for cholangiocarcinoma: implications for follow-up?
  • METHODS: We report a patient who developed recurrence 8 years after resection of cholangiocarcinoma.
  • Descriptions of late recurrence after excision of cholangiocarcinoma are reviewed.
  • There is a need to differentiate a new primary and field change from recurrence of the previous tumor.
  • CONCLUSIONS: Long-term follow-up after resection of cholangiocarcinoma is needed because late recurrence after 5 years occurs.
  • The mortality rate between 5 and 10 years after resection of cholangiocarcinoma ranges from 6% to 43% in different series.
  • [MeSH-major] Bile Duct Neoplasms / surgery. Bile Ducts, Intrahepatic / surgery. Biliary Tract Surgical Procedures. Bone Neoplasms / secondary. Cholangiocarcinoma / surgery. Liver Neoplasms / secondary
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cell Differentiation. Chemotherapy, Adjuvant. Fatal Outcome. Humans. Male. Neoplasm Invasiveness. Palliative Care. Radiotherapy, Adjuvant. Time Factors

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18842505.001).
  • [ISSN] 1499-3872
  • [Journal-full-title] Hepatobiliary & pancreatic diseases international : HBPD INT
  • [ISO-abbreviation] HBPD INT
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China
  •  go-up   go-down


6. Hong CK, Yang JM, Kang BK, Kim JD, Kim YC, Chang UI, Yoo JY: A case of combined hepatocellular-cholangiocarcinoma with underlying schistosomiasis. Korean J Intern Med; 2007 Dec;22(4):283-6
Genetic Alliance. consumer health - Schistosomiasis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of combined hepatocellular-cholangiocarcinoma with underlying schistosomiasis.
  • Combined hepatocellular-cholangiocarcinoma is a rare form of primary liver cancer showing features of both hepatocellular and biliary epithelial differentiation.
  • We report here on a case with collision tumor, which apparently was the coincidental occurrence of both hepatocellular carcinoma and cholangiocarcinoma underlying schistosomiasis.
  • Partial lobectomy was performed and we histologically identified the concurrent occurrence of hepatocellular carcinoma and cholangiocarcinoma, (a "collision type carcinoma").
  • [MeSH-major] Carcinoma, Hepatocellular / diagnosis. Cholangiocarcinoma / diagnosis. Schistosomiasis / physiopathology
  • [MeSH-minor] Adenocarcinoma / diagnosis. Adenocarcinoma / pathology. Adenocarcinoma / surgery. Adult. Female. Humans

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Dig Dis Sci. 2000 Feb;45(2):317-24 [10711445.001]
  • [Cites] Gut. 2000 Nov;47(5):721-7 [11034592.001]
  • [Cites] Clin Cancer Res. 2001 Sep;7(9):2648-55 [11555575.001]
  • [Cites] J Hepatol. 2001 Aug;35(2):235-44 [11580146.001]
  • [Cites] Cancer. 1984 Oct 15;54(8):1747-55 [6089997.001]
  • [Cites] Cancer. 1985 Jan 1;55(1):124-35 [2578078.001]
  • [Cites] Am J Pathol. 1949 Jul;25(4):647-55 [18152860.001]
  • [Cites] Am J Pathol. 1987 Jun;127(3):530-7 [2438941.001]
  • [Cites] Pathol Res Pract. 1987 Dec;182(6):783-91 [2449680.001]
  • [Cites] Am J Surg Pathol. 1988 Mar;12(3):187-97 [2449824.001]
  • [Cites] J Pathol. 1988 Dec;156(4):305-10 [2465399.001]
  • [Cites] Am J Surg Pathol. 1991 Mar;15(3):280-8 [1847609.001]
  • [Cites] Liver. 1995 Feb;15(1):9-15 [7539881.001]
  • [Cites] Am J Clin Pathol. 1987 Feb;87(2):168-73 [3028121.001]
  • (PMID = 18309689.001).
  • [ISSN] 1226-3303
  • [Journal-full-title] The Korean journal of internal medicine
  • [ISO-abbreviation] Korean J. Intern. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2687661
  •  go-up   go-down


7. Lee WS, Lee KW, Heo JS, Kim SJ, Choi SH, Kim YI, Joh JW: Comparison of combined hepatocellular and cholangiocarcinoma with hepatocellular carcinoma and intrahepatic cholangiocarcinoma. Surg Today; 2006;36(10):892-7
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparison of combined hepatocellular and cholangiocarcinoma with hepatocellular carcinoma and intrahepatic cholangiocarcinoma.
  • PURPOSE: Combined hepatocellular and cholangiocarcinoma (HCC-CC) is a rare primary hepatic neoplasm (PHN) with features of both hepatocellular and biliary differentiation.
  • We compared the outcome of hepatic resection in patients with HCC-CC, those with hepatocellular carcinoma (HCC), and those with cholangiocarcinoma (ICC).
  • [MeSH-major] Bile Duct Neoplasms / pathology. Bile Ducts, Intrahepatic / pathology. Carcinoma, Hepatocellular / pathology. Cholangiocarcinoma / pathology. Liver Neoplasms / pathology. Neoplasms, Multiple Primary
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Female. Follow-Up Studies. Hepatectomy. Humans. Male. Middle Aged. Prognosis. Retrospective Studies. Survival Rate

  • Genetic Alliance. consumer health - Intrahepatic cholangiocarcinoma.
  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16998683.001).
  • [ISSN] 0941-1291
  • [Journal-full-title] Surgery today
  • [ISO-abbreviation] Surg. Today
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


8. Melum E, Karlsen TH, Schrumpf E, Bergquist A, Thorsby E, Boberg KM, Lie BA: Cholangiocarcinoma in primary sclerosing cholangitis is associated with NKG2D polymorphisms. Hepatology; 2008 Jan;47(1):90-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cholangiocarcinoma in primary sclerosing cholangitis is associated with NKG2D polymorphisms.
  • Primary sclerosing cholangitis (PSC) is often complicated by the development of cholangiocarcinoma (CCA).
  • [MeSH-major] Bile Duct Neoplasms / genetics. Bile Ducts, Intrahepatic. Cholangiocarcinoma / genetics. Cholangitis, Sclerosing / complications. Histocompatibility Antigens Class I / genetics. Receptors, Immunologic / genetics
  • [MeSH-minor] Adolescent. Adult. Aged. Alleles. Case-Control Studies. Child. Genetic Predisposition to Disease. Humans. Middle Aged. NK Cell Lectin-Like Receptor Subfamily K. Polymorphism, Single Nucleotide. Receptors, Natural Killer Cell

  • Genetic Alliance. consumer health - Primary sclerosing cholangitis.
  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Hepatology. 2008 Jan;47(1):8-10 [18161699.001]
  • (PMID = 18023027.001).
  • [ISSN] 1527-3350
  • [Journal-full-title] Hepatology (Baltimore, Md.)
  • [ISO-abbreviation] Hepatology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Histocompatibility Antigens Class I; 0 / KLRK1 protein, human; 0 / MHC class I-related chain A; 0 / NK Cell Lectin-Like Receptor Subfamily K; 0 / Receptors, Immunologic; 0 / Receptors, Natural Killer Cell
  •  go-up   go-down


9. Boberg KM, Jebsen P, Clausen OP, Foss A, Aabakken L, Schrumpf E: Diagnostic benefit of biliary brush cytology in cholangiocarcinoma in primary sclerosing cholangitis. J Hepatol; 2006 Oct;45(4):568-74
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnostic benefit of biliary brush cytology in cholangiocarcinoma in primary sclerosing cholangitis.
  • BACKGROUND/AIMS: Primary sclerosing cholangitis (PSC) is associated with a high risk of cholangiocarcinoma development.
  • RESULTS: Among patients with cytological low-grade (n=9; 15%) or high-grade dysplasia/adenocarcinoma (n=13; 21%), 8 (36%) proved to have cholangiocarcinoma and 7 (32%) to have high-grade dysplasia (i.e. cholangiocarcinoma in situ) in bile ducts from explanted livers.
  • CONCLUSIONS: Brush cytology from bile duct strictures in PSC patients can detect cholangiocarcinoma in situ.
  • [MeSH-major] Bile Duct Neoplasms / pathology. Bile Ducts, Intrahepatic / pathology. Biopsy / methods. Cholangiocarcinoma / pathology. Cholangitis, Sclerosing / pathology
  • [MeSH-minor] Adenocarcinoma / pathology. Adolescent. Adult. Aged. Biomarkers, Tumor. Carcinoma in Situ / pathology. Cholangiopancreatography, Endoscopic Retrograde. Female. Humans. Male. Middle Aged. Predictive Value of Tests. Prospective Studies. Sensitivity and Specificity

  • Genetic Alliance. consumer health - Primary sclerosing cholangitis.
  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • MedlinePlus Health Information. consumer health - Biopsy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Hepatol. 2006 Oct;45(4):476-9 [16901574.001]
  • (PMID = 16879890.001).
  • [ISSN] 0168-8278
  • [Journal-full-title] Journal of hepatology
  • [ISO-abbreviation] J. Hepatol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


10. Fevery J, Verslype C, Lai G, Aerts R, Van Steenbergen W: Incidence, diagnosis, and therapy of cholangiocarcinoma in patients with primary sclerosing cholangitis. Dig Dis Sci; 2007 Nov;52(11):3123-35
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Incidence, diagnosis, and therapy of cholangiocarcinoma in patients with primary sclerosing cholangitis.
  • Primary sclerosing cholangitis (PSC) can lead to the development of cholangiocarcinoma (CCA).
  • The tumor may present as an intrahepatic focal cholangiocellular carcinoma but more often as a ductal infiltrating desmoplastic lesion.
  • [MeSH-major] Bile Duct Neoplasms / epidemiology. Bile Ducts, Intrahepatic. Cholangiocarcinoma / epidemiology. Cholangitis, Sclerosing / complications
  • [MeSH-minor] Adolescent. Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Belgium / epidemiology. Biopsy. Brachytherapy / methods. Cholangiopancreatography, Endoscopic Retrograde. Diagnosis, Differential. Disease Progression. Endosonography. Fatal Outcome. Female. Follow-Up Studies. Humans. Incidence. Magnetic Resonance Imaging. Male. Positron-Emission Tomography. Retrospective Studies. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Primary sclerosing cholangitis.
  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17431781.001).
  • [ISSN] 0163-2116
  • [Journal-full-title] Digestive diseases and sciences
  • [ISO-abbreviation] Dig. Dis. Sci.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


11. Tischoff I, Tannapfel A: [Hepatocellular carcinoma and cholangiocarcinoma--different prognosis, pathogenesis and therapy]. Zentralbl Chir; 2007 Aug;132(4):300-5
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Hepatocellular carcinoma and cholangiocarcinoma--different prognosis, pathogenesis and therapy].
  • Primary liver cancer is one of the most common cancer worldwide.
  • Beside hepatocellular carcinoma (HCC), accounting for more than 80%, cholangiocarcinoma (CC) is the second most frequent primary malignant epithelial liver tumor.
  • Combined hepatocellular-cholangiocarcinoma (HCC/CC) is a rare form of liver cancer with a frequency of 1%.
  • Both, hepatocellular carcinoma and cholangiocarcinoma, show a wide geographical variation with low-incidence areas in North America and Europe and high incidence areas in Africa and Asia.
  • 70-80% of hepatocellular carcinoma occur in cirrhotic liver.
  • The etiology of cholangiocarcinoma remains unclear, most occur in absence of known etiological factors.
  • [MeSH-major] Bile Duct Neoplasms. Bile Ducts, Intrahepatic. Carcinoma, Hepatocellular. Cholangiocarcinoma. Liver Neoplasms
  • [MeSH-minor] Adult. Diagnosis, Differential. Female. Humans. Incidence. Liver / pathology. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Staging. Prognosis. Risk Factors. Time Factors

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17724632.001).
  • [ISSN] 0044-409X
  • [Journal-full-title] Zentralblatt für Chirurgie
  • [ISO-abbreviation] Zentralbl Chir
  • [Language] ger
  • [Publication-type] Comparative Study; English Abstract; Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 33
  •  go-up   go-down


12. Oh HC, Kim MH, Lee KT, Lee JK, Moon SH, Song TJ, Eum J, Park DH, Lee SS, Seo DW, Lee SK: Clinical clues to suspicion of IgG4-associated sclerosing cholangitis disguised as primary sclerosing cholangitis or hilar cholangiocarcinoma. J Gastroenterol Hepatol; 2010 Dec;25(12):1831-7
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical clues to suspicion of IgG4-associated sclerosing cholangitis disguised as primary sclerosing cholangitis or hilar cholangiocarcinoma.
  • BACKGROUND AND AIM: This study aimed to determine the clinical characteristics of immunoglobulin G4 (IgG4)-associated sclerosing cholangitis (ISC) and provide clinical clues differentiating ISC from primary sclerosing cholangitis (PSC) or hilar cholangiocarcinoma (CCC).
  • [MeSH-major] Bile Duct Neoplasms / diagnosis. Bile Ducts, Intrahepatic. Cholangiocarcinoma / diagnosis. Cholangitis, Sclerosing / diagnosis. Immunoglobulin G / blood
  • [MeSH-minor] Adult. Aged. Biomarkers / blood. Biopsy. Cholangiography. Cholangiopancreatography, Magnetic Resonance. Constriction, Pathologic. Diagnosis, Differential. Female. Humans. Male. Middle Aged. Predictive Value of Tests. Prospective Studies. Republic of Korea. Steroids / therapeutic use. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Primary sclerosing cholangitis.
  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2010 Journal of Gastroenterology and Hepatology Foundation and Blackwell Publishing Asia Pty Ltd.
  • (PMID = 21091993.001).
  • [ISSN] 1440-1746
  • [Journal-full-title] Journal of gastroenterology and hepatology
  • [ISO-abbreviation] J. Gastroenterol. Hepatol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Immunoglobulin G; 0 / Steroids
  •  go-up   go-down


13. Charatcharoenwitthaya P, Enders FB, Halling KC, Lindor KD: Utility of serum tumor markers, imaging, and biliary cytology for detecting cholangiocarcinoma in primary sclerosing cholangitis. Hepatology; 2008 Oct;48(4):1106-17
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Utility of serum tumor markers, imaging, and biliary cytology for detecting cholangiocarcinoma in primary sclerosing cholangitis.
  • There is limited information on test performance for detecting cholangiocarcinoma in primary sclerosing cholangitis (PSC), particularly when used sequentially.
  • This study aimed to characterize diagnostic performance of serum carbohydrate antigen 19-9 (CA 19-9), ultrasonography, computed tomography, magnetic resonance imaging, cholangiography, and biliary cytologic techniques for detecting cholangiocarcinoma in PSC.
  • All consecutive patients with PSC were screened and followed for development of cholangiocarcinoma from 2000 through 2006.
  • Of 230 patients, 23 developed cytopathologically confirmed cholangiocarcinoma with an annual incidence of 1.2%.
  • Following this group, conventional cytology, aneuploidy detection by digital imaging analysis, and aneusomy detection by fluorescence in situ hybridization in brushing samples of biliary strictures had a sensitivity of 50%, 57%, and 86%, specificity of 97%, 94%, and 83%, PPV of 86%, 89%, and 80%, and NPV of 83%, 74%, and 88%, respectively, for detecting cholangiocarcinoma.
  • CONCLUSION: Tumor serology combined with cross-sectional liver imaging may be useful as a screening strategy and cholangiography with cytologic examination is helpful for the diagnosis of cholangiocarcinoma in patients with PSC.
  • [MeSH-major] Bile Duct Neoplasms / etiology. Bile Duct Neoplasms / pathology. Bile Ducts, Intrahepatic. CA-19-9 Antigen / blood. Cholangiocarcinoma / etiology. Cholangiocarcinoma / pathology. Cholangitis, Sclerosing / complications
  • [MeSH-minor] Adult. Aged. Biomarkers, Tumor / blood. Female. Humans. Liver / pathology. Liver / radiography. Liver / ultrasonography. Male. Mass Screening. Middle Aged. Predictive Value of Tests. Retrospective Studies. Sensitivity and Specificity

  • Genetic Alliance. consumer health - Primary sclerosing cholangitis.
  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18785620.001).
  • [ISSN] 1527-3350
  • [Journal-full-title] Hepatology (Baltimore, Md.)
  • [ISO-abbreviation] Hepatology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CA-19-9 Antigen
  •  go-up   go-down


14. Moff SL, Clark DP, Maitra A, Pandey A, Thuluvath PJ: Utility of bile duct brushings for the early detection of cholangiocarcinoma in patients with primary sclerosing cholangitis. J Clin Gastroenterol; 2006 Apr;40(4):336-41
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Utility of bile duct brushings for the early detection of cholangiocarcinoma in patients with primary sclerosing cholangitis.
  • BACKGROUND: In patients with primary sclerosing cholangitis, there are no reliable markers or imaging modalities to detect malignant changes or early cholangiocarcinoma when curative interventions may still be possible.
  • Three of six patients with marked atypia have undergone transplantation for these abnormal findings, and of these, two had cholangiocarcinoma and one had no cancer detected in the explant.
  • Two patients with benign findings developed cholangiocarcinoma, whereas 29 others have not.
  • CONCLUSION: Cytopathologic examination of bile duct brushings taken at ERCP may be useful for the early detection of malignant changes in patients with primary sclerosing cholangitis.
  • [MeSH-major] Bile Duct Neoplasms / diagnosis. Bile Ducts / cytology. Bile Ducts, Intrahepatic. Cholangiocarcinoma / diagnosis. Cholangitis, Sclerosing / complications
  • [MeSH-minor] Adult. Cholangiopancreatography, Endoscopic Retrograde. Constriction, Pathologic. Female. Humans. Male. Middle Aged. Retrospective Studies. Specimen Handling. Treatment Outcome

  • Genetic Alliance. consumer health - Primary sclerosing cholangitis.
  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Clin Gastroenterol. 2006 Apr;40(4):279-80 [16633096.001]
  • (PMID = 16633106.001).
  • [ISSN] 0192-0790
  • [Journal-full-title] Journal of clinical gastroenterology
  • [ISO-abbreviation] J. Clin. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


15. He F, Yan Q, Fan L, Liu Y, Cui J, Wang J, Wang L, Wang Y, Wang Z, Guo Y, Huang G: PBK/TOPK in the differential diagnosis of cholangiocarcinoma from hepatocellular carcinoma and its involvement in prognosis of human cholangiocarcinoma. Hum Pathol; 2010 Mar;41(3):415-24
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] PBK/TOPK in the differential diagnosis of cholangiocarcinoma from hepatocellular carcinoma and its involvement in prognosis of human cholangiocarcinoma.
  • In this study, we analyzed PBK/TOPK expression in hepatic primary tumor and explored its role in cholangiocarcinoma biology.
  • The protein, mRNA of PBK/TOPK, and cell cycle of cholangiocarcinoma cell line after PBK/TOPK suppression with small interfere RNA were studied by Western blot, semiquantitative reverse transcriptase-polymerase chain reaction, and flow cytometry, respectively.
  • PBK/TOPK was usually expressed in normal bile duct epithelial cells and much more frequently expressed in cholangiocarcinoma (68/74) but never expressed in hepatocytes and hepatocellular carcinomas (0/33).
  • PBK/TOPK down-regulation was related to the poor prognosis of patients with cholangiocarcinoma (P = .013).
  • Epidermal growth factor can enhance PBK/TOPK expression in cholangiocarcinoma QBC 939 cells, but suppression of PBK/TOPK in the cells did not affect their proliferation.
  • PBK/TOPK protein could serve as a useful indicator for histopathologic differentiation between cholangiocarcinoma and hepatocellular carcinomas and the low expression of PBK/TOPK is predicative of poor survival in cholangiocarcinoma patients.
  • [MeSH-major] Carcinoma, Hepatocellular / diagnosis. Cholangiocarcinoma / diagnosis. Liver Neoplasms / diagnosis. Protein-Serine-Threonine Kinases / metabolism
  • [MeSH-minor] Adult. Aged. Bile Ducts / metabolism. Blotting, Western. Cell Cycle / physiology. Cell Line, Tumor. Cells, Cultured. Diagnosis, Differential. Epithelial Cells / metabolism. Female. Flow Cytometry. Gene Silencing. Humans. Immunohistochemistry. Kaplan-Meier Estimate. Male. Middle Aged. Mitogen-Activated Protein Kinase Kinases. Prognosis. Proportional Hazards Models. RNA, Messenger / genetics. RNA, Messenger / metabolism. Reverse Transcriptase Polymerase Chain Reaction. Sex Factors

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Inc. All rights reserved.
  • (PMID = 19954816.001).
  • [ISSN] 1532-8392
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / RNA, Messenger; EC 2.7.11.1 / Protein-Serine-Threonine Kinases; EC 2.7.12.2 / Mitogen-Activated Protein Kinase Kinases; EC 2.7.12.2 / PDZ-binding kinase
  •  go-up   go-down


16. Flood WA, Lewis LD: A phase I study of intravenous (IV) milataxel in combination with carboplatin in adult patients with advanced malignant solid tumors. J Clin Oncol; 2009 May 20;27(15_suppl):e13525

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase I study of intravenous (IV) milataxel in combination with carboplatin in adult patients with advanced malignant solid tumors.
  • The primary objective of this study was to determine the MTD when MXL was given intravenously in combination with a fixed dose (AUC=6) of carboplatin (C) every 21 days in subjects with advanced malignant solid tumors.
  • METHODS: Key subject eligibility criteria included: adult pts with refractory malignant tumors, ECOG PS <3 and adequate hematologic, hepatic and renal function.
  • One pt in the MTD cohort with cholangiocarcinoma had a PR.
  • One patient with a cholangiocarcinoma had a sustained PR for 378 days.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961283.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


17. Morris-Stiff G, Bhati C, Olliff S, Hübscher S, Gunson B, Mayer D, Mirza D, Buckels J, Bramhall SR: Cholangiocarcinoma complicating primary sclerosing cholangitis: a 24-year experience. Dig Surg; 2008;25(2):126-32
Genetic Alliance. consumer health - Primary sclerosing cholangitis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cholangiocarcinoma complicating primary sclerosing cholangitis: a 24-year experience.
  • AIM: To report the prevalence and outcome of cholangiocarcinoma arising in primary sclerosing cholangitis for a British tertiary referral centre.
  • METHODS: All patients diagnosed with primary sclerosing cholangitis and concurrent cholangiocarcinoma were identified from a prospectively maintained departmental database, and the mode of presentation, management and outcome were determined.
  • RESULTS: Of 370 patients with primary sclerosing cholangitis, 48 patients (13%) were diagnosed with a cholangiocarcinoma within a median time of 0.51 months (range: 0-73.12) from presentation to the unit.
  • Mode of presentation included: inoperable tumours (n = 14); incidental findings in transplant hepatectomy specimens (n = 13); primary sclerosing cholangitis follow-up (n = 9); transplant work-up (n = 5); transplant waiting list (n = 5); suspected tumour confirmed at transplant (n = 1), and incidental finding at cholecystectomy (n = 1).
  • CONCLUSIONS: Cholangiocarcinoma is a common finding in primary sclerosing cholangitis and regular screening of this cohort of patients at referring centres is advocated to detect early tumours, as surgical treatment at an early stage offers significantly better outcomes for this cohort of patients.
  • [MeSH-major] Cholangiocarcinoma / complications. Cholangitis, Sclerosing / complications
  • [MeSH-minor] Adult. Aged. Bile Duct Neoplasms / complications. Bile Duct Neoplasms / mortality. Bile Duct Neoplasms / surgery. Bile Ducts, Intrahepatic. Female. Hepatectomy. Humans. Liver Transplantation. Male. Middle Aged. Prospective Studies. Stents

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2008 S. Karger AG, Basel.
  • (PMID = 18446034.001).
  • [ISSN] 1421-9883
  • [Journal-full-title] Digestive surgery
  • [ISO-abbreviation] Dig Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


18. Portolani N, Baiocchi GL, Coniglio A, Piardi T, Grazioli L, Benetti A, Ferrari Bravo A, Giulini SM: Intrahepatic cholangiocarcinoma and combined hepatocellular-cholangiocarcinoma: a Western experience. Ann Surg Oncol; 2008 Jul;15(7):1880-90
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intrahepatic cholangiocarcinoma and combined hepatocellular-cholangiocarcinoma: a Western experience.
  • BACKGROUND: Intrahepatic cholangiocarcinoma (ICC) is an unusual tumour.
  • METHODS: The clinicopathological data of 67 patients with ICC and combined hepatocellular-cholangiocarcinoma (HCC-ICC) are presented.
  • [MeSH-major] Bile Duct Neoplasms / pathology. Bile Ducts, Intrahepatic / pathology. Carcinoma, Hepatocellular / pathology. Cholangiocarcinoma / pathology. Liver Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Hepatitis B / complications. Hepatitis C / complications. Humans. Liver Cirrhosis / complications. Male. Middle Aged. Neoplasm Staging. Neoplasms, Multiple Primary. Prognosis. Risk Factors. Survival Rate

  • Genetic Alliance. consumer health - Intrahepatic cholangiocarcinoma.
  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18443881.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


19. Albiin N, Smith IC, Arnelo U, Lindberg B, Bergquist A, Dolenko B, Bryksina N, Bezabeh T: Detection of cholangiocarcinoma with magnetic resonance spectroscopy of bile in patients with and without primary sclerosing cholangitis. Acta Radiol; 2008 Oct;49(8):855-62
Hazardous Substances Data Bank. CHOLESTEROL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detection of cholangiocarcinoma with magnetic resonance spectroscopy of bile in patients with and without primary sclerosing cholangitis.
  • BACKGROUND: Early detection of cholangiocarcinoma (CC) is very difficult, especially in patients with primary sclerosing cholangitis (PSC) who are at increased risk of developing CC.
  • CONCLUSION: With 1H-MRS of bile, cholangiocarcinoma could be discriminated from benign biliary conditions with or without PSC.
  • [MeSH-major] Bile / chemistry. Bile Duct Neoplasms / diagnosis. Bile Ducts, Intrahepatic. Cholangiocarcinoma / diagnosis. Cholangitis, Sclerosing / complications. Magnetic Resonance Spectroscopy / methods
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Bile Acids and Salts / analysis. Biomarkers, Tumor / analysis. Cholesterol / analysis. Diagnosis, Differential. Female. Humans. Lipids / analysis. Male. Middle Aged. Multivariate Analysis. Phosphatidylcholines / analysis. Reproducibility of Results. Sensitivity and Specificity

  • Genetic Alliance. consumer health - Primary sclerosing cholangitis.
  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18608012.001).
  • [ISSN] 1600-0455
  • [Journal-full-title] Acta radiologica (Stockholm, Sweden : 1987)
  • [ISO-abbreviation] Acta Radiol
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] Sweden
  • [Chemical-registry-number] 0 / Bile Acids and Salts; 0 / Biomarkers, Tumor; 0 / Lipids; 0 / Phosphatidylcholines; 97C5T2UQ7J / Cholesterol
  •  go-up   go-down


20. Shinohara ET, Guo M, Mitra N, Metz JM: Brachytherapy in the treatment of cholangiocarcinoma. Int J Radiat Oncol Biol Phys; 2010 Nov 1;78(3):722-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Brachytherapy in the treatment of cholangiocarcinoma.
  • METHODS AND MATERIALS: Using the Surveillance, Epidemiology and End Results database, a total of 193 patients with cholangiocarcinoma treated with brachytherapy were identified for the period 1988-2003.
  • The primary analysis compared patients treated with brachytherapy (with or without external-beam radiation) with those who did not receive radiation.
  • [MeSH-major] Bile Duct Neoplasms / radiotherapy. Bile Ducts, Intrahepatic. Brachytherapy. Cholangiocarcinoma / radiotherapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Analysis of Variance. Female. Humans. Male. Middle Aged. Retrospective Studies. Young Adult

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20207503.001).
  • [ISSN] 1879-355X
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


21. Lewis JT, Talwalkar JA, Rosen CB, Smyrk TC, Abraham SC: Precancerous bile duct pathology in end-stage primary sclerosing cholangitis, with and without cholangiocarcinoma. Am J Surg Pathol; 2010 Jan;34(1):27-34
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Precancerous bile duct pathology in end-stage primary sclerosing cholangitis, with and without cholangiocarcinoma.
  • Patients with primary sclerosing cholangitis (PSC) are at increased risk for developing cholangiocarcinoma (CCA).
  • These data strongly support a metaplasia-low-grade dysplasia-high-grade dysplasia-carcinoma sequence in PSC-associated CCA, and underscore the known lack of relationship between patient age and PSC duration in the development of CCA.
  • [MeSH-major] Bile Duct Neoplasms / pathology. Bile Ducts, Intrahepatic / pathology. Cholangiocarcinoma / pathology. Cholangitis, Sclerosing / pathology. Precancerous Conditions / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Female. Humans. Male. Metaplasia. Middle Aged. Retrospective Studies. Young Adult

  • Genetic Alliance. consumer health - Primary sclerosing cholangitis.
  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19898228.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


22. Aishima S, Kuroda Y, Asayama Y, Taguchi K, Nishihara Y, Taketomi A, Tsuneyoshi M: Prognostic impact of cholangiocellular and sarcomatous components in combined hepatocellular and cholangiocarcinoma. Hum Pathol; 2006 Mar;37(3):283-91
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic impact of cholangiocellular and sarcomatous components in combined hepatocellular and cholangiocarcinoma.
  • Combined hepatocellular and cholangiocarcinoma (cHC-CC) is a rare type of liver cancer displaying both hepatocellular and cholangiocellular components.
  • The cholangiocellular carcinoma (CC) in these tumors ranges from focal to prominent.
  • The Ki-67 labeling index values for the hepatocellular carcinoma, CC, and sarcomatous components were 11.4% +/- 12.9%, 25.4% +/- 18.3%, and 46.0% +/- 23.6%, respectively.
  • [MeSH-major] Bile Duct Neoplasms / pathology. Bile Ducts, Intrahepatic / pathology. Carcinoma, Hepatocellular / secondary. Cholangiocarcinoma / secondary. Liver Neoplasms / pathology. Sarcoma / secondary
  • [MeSH-minor] Adult. Aged. Biomarkers, Tumor / analysis. Disease-Free Survival. Female. Humans. Immunoenzyme Techniques. Male. Middle Aged. Neoplasms, Multiple Primary. Prognosis. Survival Rate

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16613323.001).
  • [ISSN] 0046-8177
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


23. Rudolph G, Kloeters-Plachky P, Rost D, Stiehl A: The incidence of cholangiocarcinoma in primary sclerosing cholangitis after long-time treatment with ursodeoxycholic acid. Eur J Gastroenterol Hepatol; 2007 Jun;19(6):487-91
MedlinePlus Health Information. consumer health - Bile Duct Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The incidence of cholangiocarcinoma in primary sclerosing cholangitis after long-time treatment with ursodeoxycholic acid.
  • BACKGROUND/AIMS: Cholangiocarcinoma represents a serious complication of primary sclerosing cholangitis.
  • Ursodeoxycholic acid may possibly influence the incidence of cholangiocarcinoma in man.
  • The aim of this study was to evaluate the incidence rate of cholangiocarcinoma in a large group of primary sclerosing cholangitis patients after long-time treatment with ursodeoxycholic acid.
  • PATIENTS AND METHODS: From May 1987 up to May 2005 a total of 150 patients with primary sclerosing cholangitis but without evidence of cholangiocarcinoma at entry were included in the study.
  • Altogether five patients developed a cholangiocarcinoma during treatment yielding a rate of 3.3%.
  • The patients developed 0.58 cholangiocarcinoma per 100 patient-years in years 0-2.5, 0.59 cholangiocarcinoma in years 2.5-8.5, and no cholangiocarcinoma thereafter up to 18 years after entry into the study.
  • The Kaplan-Meier estimate of cholangiocarcinoma incidence during ursodeoxycholic acid treatment reached a plateau after 8.3 years.
  • SUMMARY AND CONCLUSION: The annual incidence rate of cholangiocarcinoma in primary sclerosing cholangitis treated with ursodeoxycholic acid is lower than expected and decreases with time of treatment.
  • [MeSH-major] Bile Duct Neoplasms / chemically induced. Bile Ducts, Intrahepatic / drug effects. Cholagogues and Choleretics / adverse effects. Cholangiocarcinoma / chemically induced. Cholangitis, Sclerosing / drug therapy. Ursodeoxycholic Acid / adverse effects
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Cholestasis, Intrahepatic / etiology. Female. Humans. Long-Term Care / methods. Male. Middle Aged. Patient Dropouts. Prospective Studies

  • Genetic Alliance. consumer health - Primary sclerosing cholangitis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17489059.001).
  • [ISSN] 0954-691X
  • [Journal-full-title] European journal of gastroenterology & hepatology
  • [ISO-abbreviation] Eur J Gastroenterol Hepatol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Cholagogues and Choleretics; 724L30Y2QR / Ursodeoxycholic Acid
  •  go-up   go-down


24. Wakasa T, Wakasa K, Shutou T, Hai S, Kubo S, Hirohashi K, Umeshita K, Monden M: A histopathological study on combined hepatocellular and cholangiocarcinoma: cholangiocarcinoma component is originated from hepatocellular carcinoma. Hepatogastroenterology; 2007 Mar;54(74):508-13
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A histopathological study on combined hepatocellular and cholangiocarcinoma: cholangiocarcinoma component is originated from hepatocellular carcinoma.
  • BACKGROUND/AIMS: Combined hepatocellular and cholangiocarcinoma of the liver is relatively infrequent, and its pathogenesis remains obscure.
  • METHODOLOGY: In this study, we investigated the histopathological features, Ki-67 labeling index, and p53 immunohistochemistry of 18 surgically resected cases of combined hepatocellular and cholangiocarcinoma among 1102 consecutive cases of surgically resected primary liver cancers.
  • Microscopically, we classified the cases into the following three categories according to the arrangement of the hepatocellular carcinoma and cholangiocarcinoma components;.
  • (1) Type I in which hepatocellular carcinoma and cholangiocarcinoma formed nodules that could easily be distinguished from each other, (2) Type II in which the both components were finely mixed, so that the two components were almost indistinguishable, and (3) Type III in which the tumors had lobular structures with hepatocellular carcinomas existing centrally and cholangiocarcinomas existing peripherally.
  • In one case of type I, well differentiated hepatocellular carcinoma demonstrated cholangiocarcinoma in "nodules-in-nodules" fashion.
  • The average of Ki-67 labeling index of hepatocellular carcinoma component of combined hepatocellular and cholangiocarcinoma was 4.4 +/- 3.4% and the index of cholangiocarcinoma component was 11.0 +/- 8.5%, which is significantly higher than that of the hepatocellular carcinoma component.
  • In one case, the cholangiocarcinoma component was positive for p53, but the hepatocellular carcinoma component was negative.
  • In the other 4 cases, both the hepatocellular carcinoma and cholangiocarcinoma components were positive.
  • Metaplasia of hepatocellular carcinoma to intrahepatic cholangiocarcinoma is assumed to be one of the pathogenic pathways of combined hepatocellular and cholangiocarcinoma.
  • [MeSH-major] Bile Duct Neoplasms / pathology. Bile Ducts, Intrahepatic / pathology. Carcinoma, Hepatocellular / pathology. Cholangiocarcinoma / pathology. Liver Neoplasms / pathology. Neoplasms, Multiple Primary / pathology
  • [MeSH-minor] Adult. Aged. Cell Division / physiology. Cell Transformation, Neoplastic / pathology. Female. Hepatitis B, Chronic / pathology. Hepatitis C, Chronic / pathology. Humans. Immunoenzyme Techniques. Ki-67 Antigen / analysis. Liver / pathology. Male. Metaplasia. Middle Aged. Tumor Suppressor Protein p53 / analysis

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17523309.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Ki-67 Antigen; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


25. Guglielmi A, Ruzzenente A, Campagnaro T, Pachera S, Valdegamberi A, Nicoli P, Cappellani A, Malfermoni G, Iacono C: Intrahepatic cholangiocarcinoma: prognostic factors after surgical resection. World J Surg; 2009 Jun;33(6):1247-54
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intrahepatic cholangiocarcinoma: prognostic factors after surgical resection.
  • BACKGROUND: Intrahepatic cholangiocarcinoma (ICC) is the second most common primary liver tumor.
  • [MeSH-major] Bile Duct Neoplasms / mortality. Bile Ducts, Intrahepatic. Cholangiocarcinoma / mortality. Hepatectomy / methods. Liver Neoplasms / mortality
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Longitudinal Studies. Male. Middle Aged. Multivariate Analysis. Prognosis. Risk Factors. Survival Rate. Treatment Outcome


26. Boonsakan P, Thangnapakorn O, Tapaneeyakorn J, Kositchaiwat S, Bunyaratvej S: Case report combined hepatocellular and cholangiocarcinoma with sarcomatous transformation. J Med Assoc Thai; 2007 Mar;90(3):574-80
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Case report combined hepatocellular and cholangiocarcinoma with sarcomatous transformation.
  • Combined hepatocellular and cholangiocarcinoma with sarcomatous transformation was first recognized in Ramathibodi Hospital in 2005.
  • This variant of carcinoma has been increasingly reported particularly from Asian countries.
  • It is suggested that the recent change of the Thai peoples' life style to an increased consumption of fast foods containing food preservatives especially nitrate or nitrite, the nitrosamine precursor may allow heavy exposure(s) to the chemical carcinogen(s) i.e. nitrosamine(s) leading to sarcomatous transformation of the carcinoma.
  • [MeSH-major] Bile Duct Neoplasms / pathology. Bile Ducts, Intrahepatic. Carcinoma, Hepatocellular / pathology. Cholangiocarcinoma / pathology. Liver Neoplasms / pathology. Neoplasms, Multiple Primary / pathology
  • [MeSH-minor] Adult. Cell Transformation, Neoplastic. Humans. Male. Sarcoma / pathology

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17427538.001).
  • [ISSN] 0125-2208
  • [Journal-full-title] Journal of the Medical Association of Thailand = Chotmaihet thangphaet
  • [ISO-abbreviation] J Med Assoc Thai
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Thailand
  •  go-up   go-down


27. Kim KH, Lee SG, Park EH, Hwang S, Ahn CS, Moon DB, Ha TY, Song GW, Jung DH, Kim KM, Lim YS, Lee HC, Chung YH, Lee YS, Suh DJ: Surgical treatments and prognoses of patients with combined hepatocellular carcinoma and cholangiocarcinoma. Ann Surg Oncol; 2009 Mar;16(3):623-9
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgical treatments and prognoses of patients with combined hepatocellular carcinoma and cholangiocarcinoma.
  • BACKGROUND: Combined hepatocellular carcinoma and cholangiocarcinoma is a very rare form of primary liver cancer containing components of both tumor types.
  • PATIENTS AND METHODS: Of the 2427 patients who underwent hepatectomy or liver transplantation because of a primary hepatic malignancy from January 1989 to July 2006 at the Asan Medical Center, Seoul, Korea, 29 had hepatocellular carcinoma and cholangiocarcinoma as a single mixed or transitional tumor.
  • CONCLUSIONS: Patients with combined hepatocellular carcinoma and cholangiocarcinoma had poor postoperative survival rates.
  • High CA 19-9 level was associated with poorer survival, suggesting that the cholangiocarcinoma portion may be a major determining factor for patient prognosis.
  • [MeSH-major] Bile Duct Neoplasms / surgery. Bile Ducts, Intrahepatic / surgery. Carcinoma, Hepatocellular / surgery. Cholangiocarcinoma / surgery. Liver Neoplasms / surgery. Neoplasms, Multiple Primary / surgery
  • [MeSH-minor] Adult. Aged. Female. Follow-Up Studies. Hepatectomy. Humans. Liver Transplantation. Lymph Nodes / pathology. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Recurrence, Local / pathology. Neoplasm Recurrence, Local / surgery. Neoplasm Staging. Prognosis. Retrospective Studies. Risk Factors. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19130133.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


28. Shin CI, Lee JM, Kim SH, Choi JY, Lee JY, Han JK, Jo SY, Choi BI: Recurrence patterns of combined hepatocellular-cholangiocarcinoma on enhanced computed tomography. J Comput Assist Tomogr; 2007 Jan-Feb;31(1):109-15
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recurrence patterns of combined hepatocellular-cholangiocarcinoma on enhanced computed tomography.
  • OBJECTIVE: To determine whether the computed tomographic (CT) findings of primary and recurrent combined hepatocellular-cholangiocarcinoma (HCC-CC) can predict the main tumor component on histopathologic examination, and to describe the recurrence patterns of HCC-CC after surgery.
  • The main features of the primary and recurrent tumors on CT and the pathological findings were classified as hepatocellular carcinoma (HCC)-dominant and cholangiocarcinoma (CC)-dominant groups.
  • CONCLUSIONS: Contrast-enhanced CT scanning can predict the dominant component of primary and recurrent HCC-CC.
  • [MeSH-major] Bile Duct Neoplasms / radiography. Bile Ducts, Intrahepatic. Carcinoma, Hepatocellular / radiography. Cholangiocarcinoma / radiography. Liver Neoplasms / radiography. Neoplasm Recurrence, Local / radiography. Neoplasms, Multiple Primary / radiography. Tomography, X-Ray Computed
  • [MeSH-minor] Adult. Aged. Female. Humans. Male. Middle Aged. Radiographic Image Enhancement. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • MedlinePlus Health Information. consumer health - CT Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17259842.001).
  • [ISSN] 0363-8715
  • [Journal-full-title] Journal of computer assisted tomography
  • [ISO-abbreviation] J Comput Assist Tomogr
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


29. Yi B, Zhang BH, Zhang YJ, Jiang XQ, Zhang BH, Yu WL, Cheng QB, Wu MC: [Analysis of the relation between surgery and prognosis of hilar cholangiocarcinoma]. Zhonghua Wai Ke Za Zhi; 2005 Jul 1;43(13):842-5
MedlinePlus Health Information. consumer health - Bile Duct Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Analysis of the relation between surgery and prognosis of hilar cholangiocarcinoma].
  • OBJECTIVE: To explore the prognosis factors of hilar cholangiocarcinoma, and investigate the relation between operative procedure and prognosis of it.
  • METHODS: A retrospective cohort study was investigated in 198 patients with hilar cholangiocarcinoma, who were treated in our hospital from December 1997 to December 2002.
  • CONCLUSIONS: Operative procedure was the most important prognosic factor of hilar cholangiocarcinoma, radical resection still was the primary measure to cure and long term survival.
  • For irresectable hilar cholangiocarcinoma, the effect of ERBD or EMBE could not be considered to be worse than that of open operative treatment.
  • [MeSH-major] Bile Duct Neoplasms / surgery. Bile Ducts, Intrahepatic. Biliary Tract Surgical Procedures / methods. Cholangiocarcinoma / surgery. Drainage / methods
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Prognosis. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16083598.001).
  • [ISSN] 0529-5815
  • [Journal-full-title] Zhonghua wai ke za zhi [Chinese journal of surgery]
  • [ISO-abbreviation] Zhonghua Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


30. Margarit C, Escartín A, Bellmunt J, Allende E, Bilbao I: [Peripheral cholangiocarcinoma: results of surgical treatment]. Gastroenterol Hepatol; 2006 Apr;29(4):215-23
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Peripheral cholangiocarcinoma: results of surgical treatment].
  • INTRODUCTION: Peripheral cholangiocarcinoma (PC) is an uncommon primary hepatic tumor that represents 10% of hepatic resections for primary malignant tumors in our experience.
  • [MeSH-major] Cholangiocarcinoma / surgery. Liver Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Female. Humans. Male. Middle Aged. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16584691.001).
  • [ISSN] 0210-5705
  • [Journal-full-title] Gastroenterología y hepatología
  • [ISO-abbreviation] Gastroenterol Hepatol
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


31. Lee SW, Kim HJ, Park JH, Park DI, Cho YK, Sohn CI, Jeon WK, Kim BI: Clinical usefulness of 18F-FDG PET-CT for patients with gallbladder cancer and cholangiocarcinoma. J Gastroenterol; 2010 May;45(5):560-6
MedlinePlus Health Information. consumer health - Gallbladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical usefulness of 18F-FDG PET-CT for patients with gallbladder cancer and cholangiocarcinoma.
  • BACKGROUND: Reports concerning the clinical usefulness of (18)F 2-fluoro-2-deoxy-D: -glucose integrated positron emission and computed tomography ((18)F-FDG PET-CT) for patients with gallbladder cancer and cholangiocarcinoma are relatively scarce.
  • The purpose of this study was to assess the diagnostic value of PET-CT in relation to a conventional imaging modality, multidetector row CT (MDCT), for patients with gallbladder cancer and cholangiocarcinoma.
  • METHODS: Ninety-nine patients with suspected gallbladder cancer and cholangiocarcinoma who underwent both PET-CT and MDCT for initial staging were included in our study.
  • The results of these two imaging modalities for evaluating primary tumors, regional lymph nodes and distant metastases were compared with the final diagnoses based on pathological or clinical findings.
  • The overall values for the sensitivities, specificities, positive predictive values (PPVs), negative predictive values (NPVs) and the accuracies of PET-CT and MDCT for the detection of a primary tumor were 90.2, 70.6, 93.7, 60.0, 86.9% and 84.2, 70.6, 93.2, 48.0, 81.8%, respectively.
  • PET-CT demonstrated no significant advantage over MDCT for the diagnosis of a primary tumor.
  • [MeSH-major] Bile Duct Neoplasms / diagnosis. Bile Ducts, Intrahepatic. Cholangiocarcinoma / diagnosis. Gallbladder Neoplasms / diagnosis. Positron-Emission Tomography. Tomography, X-Ray Computed
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cohort Studies. Female. Fluorodeoxyglucose F18. Humans. Male. Middle Aged. Predictive Value of Tests. Radiopharmaceuticals. Reproducibility of Results. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • MedlinePlus Health Information. consumer health - CT Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20035356.001).
  • [ISSN] 1435-5922
  • [Journal-full-title] Journal of gastroenterology
  • [ISO-abbreviation] J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


32. Leelawat K, Suksumek N, Leelawat S, Lek-Uthai U: Detection of VacA gene specific for Helicobactor pylori in hepatocellular carcinoma and cholangiocarcinoma specimens of Thai patients. Southeast Asian J Trop Med Public Health; 2007 Sep;38(5):881-5
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detection of VacA gene specific for Helicobactor pylori in hepatocellular carcinoma and cholangiocarcinoma specimens of Thai patients.
  • In order to investigate and compare the presence of Helicobacter pylori VacA in primary liver cancer specimens (12 hepatocellular carcinoma and 6 cholangiocarcinoma) and control liver specimens (7 non-primary liver cancer) from Thai patients who underwent liver resection, H. pylori VacA gene was assayed in extracted DNA by real-time polymerase chain reaction.
  • The selected amplicons revealed high homology compared with H. pylori VacA sequence. H. pylori VacA gene was detected in all primary liver cancer specimens and in 71% (5/7) of control liver specimens.
  • [MeSH-major] Bacterial Proteins / genetics. Carcinoma, Hepatocellular / microbiology. Cholangiocarcinoma / microbiology. Helicobacter Infections / microbiology. Helicobacter pylori / genetics. Liver Neoplasms / microbiology
  • [MeSH-minor] Adult. Aged. Base Sequence. Female. Humans. Male. Middle Aged. Molecular Sequence Data. Polymerase Chain Reaction / methods. Thailand

  • MedlinePlus Health Information. consumer health - Helicobacter Pylori Infections.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18041306.001).
  • [ISSN] 0125-1562
  • [Journal-full-title] The Southeast Asian journal of tropical medicine and public health
  • [ISO-abbreviation] Southeast Asian J. Trop. Med. Public Health
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Thailand
  • [Chemical-registry-number] 0 / Bacterial Proteins; 0 / VacA protein, Helicobacter pylori
  •  go-up   go-down


33. Xu Y, Zhu M, Zhang S, Liu H, Li T, Qin C: Expression and prognostic value of PRL-3 in human intrahepatic cholangiocarcinoma. Pathol Oncol Res; 2010 Jun;16(2):169-75
MedlinePlus Health Information. consumer health - Bile Duct Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression and prognostic value of PRL-3 in human intrahepatic cholangiocarcinoma.
  • Phosphatase of regenerating liver (PRL)-3 is involved in the metastasis of various tumors, but the expression of PRL-3 and its possible role in primary intrahepatic cholangiocarcinoma (ICC) has not been reported yet.
  • In this study, we assessed the expression levels of PRL-3 by immunohistochemistry in 102 primary ICC samples, 62 matched lymph node metastases (LNM) and 102 adjacent normal liver tissues.
  • In primary lesion and LNM high PRL-3 expression was frequently detected.
  • Furthermore, the rate of high PRL-3 expression in LNM was higher than that in primary lesion (80.6% vs. 47.1%, P < 0.05).
  • High expression of PRL-3 in primary tumors was significantly associated with TNM (P < 0.001), T stage (P < 0.001), vascular invasion (P = 0.002), and LNM (P < 0.001).
  • [MeSH-major] Bile Duct Neoplasms / metabolism. Bile Ducts, Intrahepatic / metabolism. Biomarkers, Tumor / analysis. Cholangiocarcinoma / metabolism. Neoplasm Proteins / biosynthesis. Protein Tyrosine Phosphatases / biosynthesis
  • [MeSH-minor] Adult. Aged. Female. Humans. Immunohistochemistry. Kaplan-Meier Estimate. Lymphatic Metastasis / pathology. Male. Middle Aged. Prognosis. Proportional Hazards Models

  • Genetic Alliance. consumer health - Intrahepatic cholangiocarcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19757198.001).
  • [ISSN] 1532-2807
  • [Journal-full-title] Pathology oncology research : POR
  • [ISO-abbreviation] Pathol. Oncol. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins; EC 3.1.3.48 / PTP4A3 protein, human; EC 3.1.3.48 / Protein Tyrosine Phosphatases
  •  go-up   go-down


34. Phongkitkarun S, Srisuwan T, Sornmayura P, Jatchavala J: Combined hepatocellular and cholangiocarcinoma: CT findings with emphasis on multiphasic helical CT. J Med Assoc Thai; 2007 Jan;90(1):113-20
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combined hepatocellular and cholangiocarcinoma: CT findings with emphasis on multiphasic helical CT.
  • OBJECTIVE: To describe CT findings of patients with combined hepatocellular carcinoma and cholangiocarcinoma (HCC-CC) in correlation with clinical data and histopathological results.
  • [MeSH-major] Bile Duct Neoplasms / radiography. Bile Ducts, Intrahepatic. Carcinoma, Hepatocellular / radiography. Cholangiocarcinoma / radiography. Liver Neoplasms / radiography. Neoplasms, Multiple Primary / radiography. Tomography, Spiral Computed
  • [MeSH-minor] Adult. Aged. CA-19-9 Antigen / blood. Female. Humans. Male. Middle Aged. Radiographic Image Enhancement. Retrospective Studies. alpha-Fetoproteins / analysis

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17621741.001).
  • [ISSN] 0125-2208
  • [Journal-full-title] Journal of the Medical Association of Thailand = Chotmaihet thangphaet
  • [ISO-abbreviation] J Med Assoc Thai
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Thailand
  • [Chemical-registry-number] 0 / CA-19-9 Antigen; 0 / alpha-Fetoproteins
  •  go-up   go-down


35. Kamphues C, Seehofer D, Eisele RM, Denecke T, Pratschke J, Neumann UP, Neuhaus P: Recurrent intrahepatic cholangiocarcinoma: single-center experience using repeated hepatectomy and radiofrequency ablation. J Hepatobiliary Pancreat Sci; 2010 Jul;17(4):509-15
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recurrent intrahepatic cholangiocarcinoma: single-center experience using repeated hepatectomy and radiofrequency ablation.
  • BACKGROUND: Intrahepatic cholangiocarcinoma (IHC) is a rare liver malignancy with a rising incidence worldwide.
  • RESULTS: After a median follow-up period of 28 months after primary liver resection (12-69 months), seven patients (54%) are still alive and three of these patients (23% of the entire cohort) are regarded as disease-free.
  • One- and three-year survival after primary surgery was 92 and 52%, respectively, with an overall complication rate of 7.6%.
  • [MeSH-major] Bile Duct Neoplasms / surgery. Bile Ducts, Intrahepatic. Catheter Ablation / methods. Cholangiocarcinoma / surgery. Hepatectomy / methods. Neoplasm Recurrence, Local / surgery
  • [MeSH-minor] Adult. Aged. Biopsy. Female. Follow-Up Studies. Germany / epidemiology. Humans. Incidence. Male. Middle Aged. Reoperation. Retrospective Studies. Survival Rate / trends. Tomography, X-Ray Computed. Treatment Outcome

  • Genetic Alliance. consumer health - Intrahepatic cholangiocarcinoma.
  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20714840.001).
  • [ISSN] 1868-6982
  • [Journal-full-title] Journal of hepato-biliary-pancreatic sciences
  • [ISO-abbreviation] J Hepatobiliary Pancreat Sci
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


36. Fasanella KE, Krasinskas A, Schoedel KE, Sasatomi E, Slivka A, Whitcomb DC, Sanders M, Nodit L, Raab S, McGrath KM, Ohori NP, Khalid A: DNA mutational differences in cytological specimens from pancreatic cancer and cholangiocarcinoma. Pancreatology; 2010;10(4):429-33
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] DNA mutational differences in cytological specimens from pancreatic cancer and cholangiocarcinoma.
  • BACKGROUND/AIMS: Preoperative distinction between pancreatic cancer (PC) and extrahepatic cholangiocarcinoma (CC) is desirable due to diverging management options, and to optimize enrollment into neoadjuvant trials.
  • RESULTS: Of 33 cases studied (17 males; 16 PC, 17 CC; 10 with primary sclerosing cholangitis), a K-ras mutation was present in 14/16 (87.5%) PC and 1/17 (5.9%) CC cases (p < 0.001), sensitivity and specificity were 87.5 and 94%, respectively.
  • [MeSH-major] Bile Duct Neoplasms / genetics. Bile Ducts, Intrahepatic / pathology. Carcinoma, Pancreatic Ductal / genetics. Cholangiocarcinoma / genetics. DNA Mutational Analysis. Pancreatic Neoplasms / genetics
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cholangitis, Sclerosing / genetics. Cholangitis, Sclerosing / pathology. DNA, Neoplasm / analysis. Female. Genes, ras / genetics. Humans. Male. Microdissection. Microsatellite Instability. Middle Aged. Mutation. Predictive Value of Tests. Retrospective Studies. Sensitivity and Specificity

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 S. Karger AG, Basel.
  • (PMID = 20720444.001).
  • [ISSN] 1424-3911
  • [Journal-full-title] Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.]
  • [ISO-abbreviation] Pancreatology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / DNA, Neoplasm
  •  go-up   go-down


37. Lin G, Toh CH, Wu RC, Ko SF, Ng SH, Chou WC, Tseng JH: Combined hepatocellular cholangiocarcinoma: prognostic factors investigated by computed tomography/magnetic resonance imaging. Int J Clin Pract; 2008 Aug;62(8):1199-205
MedlinePlus Health Information. consumer health - MRI Scans.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combined hepatocellular cholangiocarcinoma: prognostic factors investigated by computed tomography/magnetic resonance imaging.
  • This study was designed to assess the clinical usefulness of imaging for predicting the prognosis of patients with combined hepatocellular cholangiocarcinoma (cHCC-CC).
  • [MeSH-major] Bile Duct Neoplasms / pathology. Bile Ducts, Intrahepatic / pathology. Carcinoma, Hepatocellular / pathology. Cholangiocarcinoma / pathology. Liver Neoplasms / pathology. Magnetic Resonance Imaging / standards. Neoplasms, Multiple Primary / pathology. Tomography, X-Ray Computed / standards
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Lymphatic Metastasis. Male. Middle Aged. Multivariate Analysis. Neoplasm Invasiveness. Neoplasm Staging. Prognosis. Survival Analysis. Survival Rate

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17537192.001).
  • [ISSN] 1742-1241
  • [Journal-full-title] International journal of clinical practice
  • [ISO-abbreviation] Int. J. Clin. Pract.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] England
  •  go-up   go-down


38. Thelen A, Scholz A, Weichert W, Wiedenmann B, Neuhaus P, Gessner R, Benckert C, Jonas S: Tumor-associated angiogenesis and lymphangiogenesis correlate with progression of intrahepatic cholangiocarcinoma. Am J Gastroenterol; 2010 May;105(5):1123-32
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumor-associated angiogenesis and lymphangiogenesis correlate with progression of intrahepatic cholangiocarcinoma.
  • OBJECTIVES: Little is known about the function of tumor-associated neovascularization in the progression of intrahepatic cholangiocarcinoma (IHC).
  • Tumors of "high" MVD displayed more frequently advanced primary tumor stages and multiple tumor nodes.
  • [MeSH-major] Bile Duct Neoplasms / pathology. Bile Ducts, Intrahepatic. Cholangiocarcinoma / pathology. Lymphangiogenesis. Neovascularization, Pathologic / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Analysis of Variance. Biopsy, Needle. Cohort Studies. Disease Progression. Disease-Free Survival. Female. Humans. Immunohistochemistry. Kaplan-Meier Estimate. Male. Middle Aged. Neoplasm Invasiveness / pathology. Neoplasm Staging. Probability. Prognosis. Proportional Hazards Models. Prospective Studies. Statistics, Nonparametric. Survival Rate

  • Genetic Alliance. consumer health - Intrahepatic cholangiocarcinoma.
  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19997097.001).
  • [ISSN] 1572-0241
  • [Journal-full-title] The American journal of gastroenterology
  • [ISO-abbreviation] Am. J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


39. Kim W, Lee JH, Kim YJ, Yoon JH, Suh KS, Lee KU, Jang JJ, Lee HS: [Analysis of prognostic factors after curative resection for combined hepatocellular and cholangiocarcinoma]. Korean J Gastroenterol; 2007 Mar;49(3):158-65
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Analysis of prognostic factors after curative resection for combined hepatocellular and cholangiocarcinoma].
  • BACKGROUND/AIMS: Combined hepatocellular and cholangiocarcinoma (HCC-CC) is a rare form of primary liver carcinoma which contains characteristics of both hepatocellular carcinoma and cholangiocarcinoma.
  • [MeSH-major] Bile Duct Neoplasms / mortality. Bile Ducts, Intrahepatic. Carcinoma, Hepatocellular / mortality. Cholangiocarcinoma / mortality. Liver Neoplasms / mortality. Neoplasm Recurrence, Local / diagnosis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Hepatectomy. Humans. Male. Middle Aged. Neoplasm Staging. Predictive Value of Tests. Prognosis. Severity of Illness Index. Survival Analysis. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18172344.001).
  • [ISSN] 1598-9992
  • [Journal-full-title] The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi
  • [ISO-abbreviation] Korean J Gastroenterol
  • [Language] kor
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Korea (South)
  •  go-up   go-down


40. Cho SY, Park SJ, Kim SH, Han SS, Kim YK, Lee KW, Lee SA, Hong EK, Lee WJ, Woo SM: Survival analysis of intrahepatic cholangiocarcinoma after resection. Ann Surg Oncol; 2010 Jul;17(7):1823-30
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Survival analysis of intrahepatic cholangiocarcinoma after resection.
  • BACKGROUND: Intrahepatic cholangiocarcinoma (ICC) is the second most common primary hepatic malignancy, but the studies for the outcome after resection of ICC are rare.
  • [MeSH-major] Bile Duct Neoplasms / mortality. Bile Ducts, Intrahepatic / pathology. Cholangiocarcinoma / mortality. Hepatectomy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chemotherapy, Adjuvant. Combined Modality Therapy. Female. Humans. Lymphatic Metastasis. Male. Middle Aged. Radiotherapy Dosage. Radiotherapy, Adjuvant. Retrospective Studies. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Intrahepatic cholangiocarcinoma.
  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20165987.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


41. Zuo HQ, Yan LN, Zeng Y, Yang JY, Luo HZ, Liu JW, Zhou LX: Clinicopathological characteristics of 15 patients with combined hepatocellular carcinoma and cholangiocarcinoma. Hepatobiliary Pancreat Dis Int; 2007 Apr;6(2):161-5
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinicopathological characteristics of 15 patients with combined hepatocellular carcinoma and cholangiocarcinoma.
  • BACKGROUND: Combined hepatocellular carcinoma and cholangiocarcinoma (cHCC-CC) is a rare subtype of primary liver cancer, and clinicopathological features of cHCC-CC have seldom been reported in detail.
  • This study was undertaken to explore the diagnosis and clinicopathological characteristics of cHCC-CC in comparison with hepatocellular carcinoma (HCC) and cholangiocarcinoma (CC), respectively.
  • [MeSH-major] Bile Duct Neoplasms / pathology. Bile Ducts, Intrahepatic. Carcinoma, Hepatocellular / pathology. Cholangiocarcinoma / pathology. Liver Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Disease Progression. Female. Humans. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Invasiveness. Portal Vein / pathology. Prognosis. Survival Analysis

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Liver Transpl. 2007 Oct;13(10):1465-6 [17972421.001]
  • (PMID = 17374575.001).
  • [ISSN] 1499-3872
  • [Journal-full-title] Hepatobiliary & pancreatic diseases international : HBPD INT
  • [ISO-abbreviation] HBPD INT
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  •  go-up   go-down


42. Zhang HY, Kong YL, Zhang HY, He XJ, Zhang H, Liu CL, Zhao G, Xiao M, Zhang XD, Feng ZQ: Hepatic portal cholangiocarcinoma: a clinical analysis of 70 cases. Hepatobiliary Pancreat Dis Int; 2008 Aug;7(4):418-21
MedlinePlus Health Information. consumer health - Bile Duct Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hepatic portal cholangiocarcinoma: a clinical analysis of 70 cases.
  • BACKGROUND: The incidence of hepatic portal cholangiocarcinoma is increasing and it is always associated with poor survival.
  • METHODS: A retrospective analysis was made on 70 patients with hepatic portal cholangiocarcinoma admitted between January 2004 and February 2007 to the General Hospital of Air Force PLA.
  • RESULTS: Forty-seven patients had hepatic duct-jejunum anastomosis after resection of hepatic portal cholangiocarcinoma.
  • CONCLUSION: Surgery is the primary therapeutic method for hepatic portal cholangiocarcinoma.
  • [MeSH-major] Anastomosis, Roux-en-Y. Bile Duct Neoplasms / surgery. Bile Ducts, Intrahepatic / surgery. Biliary Tract Surgical Procedures. Cholangiocarcinoma / surgery. Drainage
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Retrospective Studies. Survival Analysis. Time Factors. Treatment Outcome. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18693179.001).
  • [ISSN] 1499-3872
  • [Journal-full-title] Hepatobiliary & pancreatic diseases international : HBPD INT
  • [ISO-abbreviation] HBPD INT
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  •  go-up   go-down


43. Jinawath N, Chamgramol Y, Furukawa Y, Obama K, Tsunoda T, Sripa B, Pairojkul C, Nakamura Y: Comparison of gene expression profiles between Opisthorchis viverrini and non-Opisthorchis viverrini associated human intrahepatic cholangiocarcinoma. Hepatology; 2006 Oct;44(4):1025-38
MedlinePlus Health Information. consumer health - Bile Duct Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparison of gene expression profiles between Opisthorchis viverrini and non-Opisthorchis viverrini associated human intrahepatic cholangiocarcinoma.
  • Intrahepatic cholangiocarcinoma (ICC) is the second most common primary cancer in the liver, and its incidence is highest in the northeastern part of Thailand.
  • [MeSH-major] Bile Duct Neoplasms / genetics. Cholangiocarcinoma / genetics. Gene Expression Profiling. Gene Expression Regulation. Opisthorchiasis / complications
  • [MeSH-minor] Adult. Aged. Animals. Cluster Analysis. Female. Humans. Japan. Male. Middle Aged. Oligonucleotide Array Sequence Analysis. Opisthorchis / isolation & purification. RNA, Messenger / analysis. Reproducibility of Results. Thailand

  • Genetic Alliance. consumer health - Intrahepatic cholangiocarcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17006947.001).
  • [ISSN] 0270-9139
  • [Journal-full-title] Hepatology (Baltimore, Md.)
  • [ISO-abbreviation] Hepatology
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / RNA, Messenger
  •  go-up   go-down


44. Yuan SF, Li KZ, Wang L, Dou KF, Yan Z, Han W, Zhang YQ: Expression of MUC1 and its significance in hepatocellular and cholangiocarcinoma tissue. World J Gastroenterol; 2005 Aug 14;11(30):4661-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of MUC1 and its significance in hepatocellular and cholangiocarcinoma tissue.
  • AIM: To investigate the relation between MUC1 expression, distribution, and prognosis in hepatocellular and cholangiocarcinoma (HCC and CC) and cirrhotic liver tissues, and their significance in HCC and CC diagnosis.
  • METHODS: Expression and distribution of MUC1 were examined by immunohistochemical assay with anti-MUC1 mAb in 59 samples of HCC and 37 samples of CC, 20 samples of cirrhotic liver tissues, and 10 samples of normal liver tissues, seeking possible associations between MUC1 positive expression, distribution in HCC and CC (primary liver cancer, PLC) cases and the studied clinical data.
  • CONCLUSION: Expression and localization of MUC1 proteins in primary liver carcinomas (PLCs) may act as prognostic markers, and MUC1 molecules might be helpful in differential diagnosis.
  • [MeSH-major] Carcinoma, Hepatocellular / metabolism. Cholangiocarcinoma / metabolism. Liver Neoplasms / metabolism. Mucin-1 / metabolism
  • [MeSH-minor] Adult. Aged. Case-Control Studies. Female. Humans. Liver Cirrhosis / metabolism. Male. Middle Aged. Prognosis

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16094706.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Mucin-1
  • [Other-IDs] NLM/ PMC4615407
  •  go-up   go-down


45. Lang H, Sotiropoulos GC, Sgourakis G, Schmitz KJ, Paul A, Hilgard P, Zöpf T, Trarbach T, Malagó M, Baba HA, Broelsch CE: Operations for intrahepatic cholangiocarcinoma: single-institution experience of 158 patients. J Am Coll Surg; 2009 Feb;208(2):218-28
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Operations for intrahepatic cholangiocarcinoma: single-institution experience of 158 patients.
  • BACKGROUND: Intrahepatic cholangiocarcinoma (ICC) is a rare primary liver malignancy.
  • [MeSH-major] Bile Duct Neoplasms / surgery. Bile Ducts, Intrahepatic / surgery. Biliary Tract Surgical Procedures. Cholangiocarcinoma / surgery
  • [MeSH-minor] Adult. Aged. Analysis of Variance. Disease-Free Survival. Female. Hepatectomy. Humans. Kaplan-Meier Estimate. Lymphatic Metastasis. Male. Middle Aged. Multivariate Analysis. Neoplasm Invasiveness. Neoplasm Staging. Predictive Value of Tests. Prognosis. Proportional Hazards Models. Retrospective Studies. Treatment Outcome

  • Genetic Alliance. consumer health - Intrahepatic cholangiocarcinoma.
  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19228533.001).
  • [ISSN] 1879-1190
  • [Journal-full-title] Journal of the American College of Surgeons
  • [ISO-abbreviation] J. Am. Coll. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


46. Lempinen M, Isoniemi H, Mäkisalo H, Nordin A, Halme L, Arola J, Höckerstedt K, Stenman UH: Enhanced detection of cholangiocarcinoma with serum trypsinogen-2 in patients with severe bile duct strictures. J Hepatol; 2007 Nov;47(5):677-83
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Enhanced detection of cholangiocarcinoma with serum trypsinogen-2 in patients with severe bile duct strictures.
  • BACKGROUND/AIMS: Primary sclerosing cholangitis (PSC) is associated with a high risk of cholangiocarcinoma.
  • Our aim was to evaluate the diagnostic value of trypsinogen-1, trypsinogen-2, tumour-associated trypsin inhibitor, human chorionic gonadotropin beta and trypsin-2-alpha(1)-antitrypsin for cholangiocarcinoma and to compare them with CA19-9 and CEA.
  • METHODS: The study consisted of 84 patients with either PSC or cholangiocarcinoma or both referred for liver transplantation or other liver surgery.
  • RESULTS: Forty-six patients were transplanted due to PSC; in 3 of the explanted livers cholangiocarcinoma was found incidentally.
  • Twenty-nine of 38 patients with cholangiocarcinoma were candidates for intervention.
  • In all, 8 patients had both PSC and cholangiocarcinoma.
  • Receiver-operating characteristics curve analysis showed that serum trypsinogen-2 had the highest accuracy in differentiating between cholangiocarcinoma and PSC.
  • Serum trypsinogen-2 also showed the highest accuracy for differentiation between PSC and PSC with simultaneous cholangiocarcinoma with an AUC value of 0.759.
  • CONCLUSIONS: Our results suggest that serum trypsinogen-2 is a most useful marker for diagnosing patients with cholangiocarcinoma, and it is superior to serum CA19-9 and CEA.
  • [MeSH-major] Bile Duct Neoplasms / blood. Bile Duct Neoplasms / diagnosis. Bile Ducts, Intrahepatic / pathology. Biomarkers, Tumor / blood. Cholangiocarcinoma / blood. Cholangiocarcinoma / diagnosis. Trypsin / blood. Trypsinogen / blood
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. CA-19-9 Antigen / analysis. CA-19-9 Antigen / blood. Constriction, Pathologic / etiology. Diagnosis, Differential. Female. Humans. Male. Middle Aged. Predictive Value of Tests. Receptors, Cell Surface / analysis. Receptors, Cell Surface / blood. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17640760.001).
  • [ISSN] 0168-8278
  • [Journal-full-title] Journal of hepatology
  • [ISO-abbreviation] J. Hepatol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CA-19-9 Antigen; 0 / Receptors, Cell Surface; 0 / carcinoembryonic antigen binding protein, human; 103964-84-7 / PRSS2 protein, human; 9002-08-8 / Trypsinogen; EC 3.4.21.4 / Trypsin
  •  go-up   go-down


47. Khunamornpong S, Siriaunkgul S, Suprasert P, Pojchamarnwiputh S, Na Chiangmai W, Young RH: Intrahepatic cholangiocarcinoma metastatic to the ovary: a report of 16 cases of an underemphasized form of secondary tumor in the ovary that may mimic primary neoplasia. Am J Surg Pathol; 2007 Dec;31(12):1788-99
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intrahepatic cholangiocarcinoma metastatic to the ovary: a report of 16 cases of an underemphasized form of secondary tumor in the ovary that may mimic primary neoplasia.
  • The potential for adenocarcinoma metastatic to the ovary to mimic primary mucinous neoplasms is a well-known issue to surgical pathologists, most of the recent literature emphasizing pancreatic and various other origins for the ovarian metastases.
  • Thirteen presented with nonspecific pelvic symptoms similar to primary ovarian neoplasms.
  • Microscopically, surface implants were observed in 80% of tumors, multinodular growth in 48%, and infiltrative stromal invasion (including microinvasionlike foci as it would be applied if the tumors were primary) in 86%.
  • The tumors most closely mimicked primary mucinous neoplasms although a resemblance to other mullerian neoplasms was also seen.
  • Foci often mimicked mucinous borderline tumors of typical type or with intraepithelial carcinoma and benign-appearing mucinous epithelium was seen in 62% of tumors.
  • Intrahepatic cholangiocarcinoma should be included in the list of origins of possible ovarian metastatic tumors that mimic primary ovarian mucinous neoplasia, particularly in parts of the world where cholangiocarcinoma of the liver is relatively common.
  • [MeSH-major] Bile Duct Neoplasms / pathology. Cholangiocarcinoma / secondary. Ovarian Neoplasms / secondary
  • [MeSH-minor] Adult. Aged. Bile Ducts, Intrahepatic / pathology. Diagnosis, Differential. Female. Humans. Middle Aged

  • Genetic Alliance. consumer health - Intrahepatic cholangiocarcinoma.
  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18043033.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


48. Kloek JJ, van der Gaag NA, Aziz Y, Rauws EA, van Delden OM, Lameris JS, Busch OR, Gouma DJ, van Gulik TM: Endoscopic and percutaneous preoperative biliary drainage in patients with suspected hilar cholangiocarcinoma. J Gastrointest Surg; 2010 Jan;14(1):119-25
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endoscopic and percutaneous preoperative biliary drainage in patients with suspected hilar cholangiocarcinoma.
  • INTRODUCTION: Controversy exists over the preferred technique of preoperative biliary drainage (PBD) in patients with hilar cholangiocarcinoma (HCCA) requiring major liver resection.
  • RESULTS: Of these patients, 101 (88%) underwent PBD; 90 patients underwent EBD as primary procedure, and 11 PTBD.
  • [MeSH-major] Bile Duct Neoplasms / surgery. Bile Ducts, Intrahepatic. Cholangiocarcinoma / surgery. Drainage / methods. Preoperative Care
  • [MeSH-minor] Adult. Aged. Catheterization / adverse effects. Endoscopy / adverse effects. Female. Hepatectomy. Humans. Male. Middle Aged. Stents

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gastrointest Endosc. 2001 Jan;53(1):40-6 [11154487.001]
  • [Cites] Gastrointest Endosc. 2003 Jul;58(1):41-9 [12838219.001]
  • [Cites] Ann Surg. 1999 Nov;230(5):655-62 [10561089.001]
  • [Cites] Gastrointest Endosc. 2001 May;53(6):547-53 [11323577.001]
  • [Cites] Gastrointest Endosc. 2009 Jan;69(1):55-62 [18657806.001]
  • [Cites] Endoscopy. 2008 Aug;40(8):625-30 [18680074.001]
  • [Cites] Cochrane Database Syst Rev. 2008;(3):CD005444 [18677779.001]
  • [Cites] Clin Gastroenterol Hepatol. 2008 Aug;6(8):944-950.e3 [18585976.001]
  • [Cites] Eur Radiol. 2008 Mar;18(3):448-56 [17960388.001]
  • [Cites] Aliment Pharmacol Ther. 2007 Dec;26 Suppl 2:127-32 [18081656.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 2007;14(5):441-6 [17909711.001]
  • [Cites] BMC Surg. 2007;7:3 [17352805.001]
  • [Cites] Am J Surg. 2007 Feb;193(2):149-54 [17236839.001]
  • [Cites] Endoscopy. 2006 Aug;38(8):787-92 [17001568.001]
  • [Cites] Gastrointest Endosc. 2006 Jun;63(7):986-95 [16733114.001]
  • [Cites] World J Gastroenterol. 2005 Nov 28;11(44):7024-7 [16437610.001]
  • [Cites] Gastroenterology. 2005 May;128(6):1655-67 [15887157.001]
  • [Cites] Hepatogastroenterology. 2005 Jan-Feb;52(61):45-7 [15782991.001]
  • [Cites] Gastrointest Endosc. 1999 Apr;49(4 Pt 1):466-71 [10202060.001]
  • [Cites] Endoscopy. 1998 Oct;30(8):681-6 [9865556.001]
  • [Cites] Gastrointest Endosc. 1998 May;47(5):354-62 [9609426.001]
  • [Cites] Arch Surg. 1995 Jul;130(7):759-63 [7611866.001]
  • [Cites] Endoscopy. 1993 Mar;25(3):213-8 [7686100.001]
  • [Cites] Gastrointest Endosc. 1993 Jan-Feb;39(1):43-9 [7681018.001]
  • [Cites] Gastrointest Endosc. 1991 May-Jun;37(3):383-93 [2070995.001]
  • [Cites] Am J Surg. 1989 Apr;157(4):395-9 [2539024.001]
  • [Cites] Lancet. 1987 Jul 11;2(8550):57-62 [2439854.001]
  • [Cites] Ann Surg. 2001 Oct;234(4):507-17; discussion 517-9 [11573044.001]
  • [Cites] Langenbecks Arch Surg. 2002 Jul;387(3-4):117-24 [12172855.001]
  • [Cites] Radiology. 2002 Oct;225(1):27-34 [12354980.001]
  • [Cites] Arch Surg. 2003 Feb;138(2):185-91 [12578418.001]
  • [Cites] Ann Surg. 2003 Jul;238(1):84-92 [12832969.001]
  • [Cites] J Clin Gastroenterol. 2004 Jul;38(6):518-23 [15220688.001]
  • [Cites] Surg Gynecol Obstet. 1975 Feb;140(2):170-8 [1079096.001]
  • [Cites] N Engl J Med. 1979 Dec 20;301(25):1364-9 [503167.001]
  • [Cites] Gut. 1983 Sep;24(9):845-52 [6604001.001]
  • [Cites] Br J Surg. 1983 Sep;70(9):535-8 [6616158.001]
  • [Cites] Am J Clin Nutr. 1986 Sep;44(3):362-9 [3751957.001]
  • (PMID = 19756881.001).
  • [ISSN] 1873-4626
  • [Journal-full-title] Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  • [ISO-abbreviation] J. Gastrointest. Surg.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


49. Jabara B, Fargen KM, Beech S, Slakey DR: Diagnosis of cholangiocarcinoma: a case series and literature review. J La State Med Soc; 2009 Mar-Apr;161(2):89-94
MedlinePlus Health Information. consumer health - Bile Duct Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnosis of cholangiocarcinoma: a case series and literature review.
  • INTRODUCTION: Cholangiocarcinoma is a rare neoplasm of the bile ducts.
  • Risk factors include primary sclerosing cholangitis, Caroli's disease, infection, liver flukes, and chronic typhoid.
  • CONCLUSIONS: Despite advances in imaging techniques and surgical care, overall survival of cholangiocarcinoma remains poor.
  • [MeSH-major] Bile Duct Neoplasms / diagnosis. Bile Ducts, Intrahepatic. Cholangiocarcinoma / diagnosis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Algorithms. Biopsy. Cholangiopancreatography, Endoscopic Retrograde. Cholangiopancreatography, Magnetic Resonance. Endosonography. Female. Humans. Male. Middle Aged. Neoplasm Staging. Retrospective Studies. Risk Factors. Time Factors. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19489389.001).
  • [ISSN] 0024-6921
  • [Journal-full-title] The Journal of the Louisiana State Medical Society : official organ of the Louisiana State Medical Society
  • [ISO-abbreviation] J La State Med Soc
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


50. Maganty K, Levi D, Moon J, Bejarano PA, Arosemena L, Tzakis A, Martin P: Combined hepatocellular carcinoma and intrahepatic cholangiocarcinoma: outcome after liver transplantation. Dig Dis Sci; 2010 Dec;55(12):3597-601
MedlinePlus Health Information. consumer health - Liver Transplantation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combined hepatocellular carcinoma and intrahepatic cholangiocarcinoma: outcome after liver transplantation.
  • BACKGROUND: Combined hepatocellular carcinoma and intrahepatic cholangiocarcinoma is a rare hepatobiliary malignancy incorporating components derived from both hepatocyte and intrahepatic bile duct epithelium.
  • The natural history, treatment, and prognosis of this distinct cancer differ from hepatocellular carcinoma (HCC) or cholangiocarcinoma (CC) and are not completely understood.
  • [MeSH-major] Bile Duct Neoplasms / surgery. Bile Ducts, Intrahepatic. Carcinoma, Hepatocellular / surgery. Cholangiocarcinoma / surgery. Liver Neoplasms / surgery. Liver Transplantation. Neoplasms, Multiple Primary / surgery
  • [MeSH-minor] Adult. Fatal Outcome. Female. Gastroenterology / standards. Hepatitis B / complications. Hepatitis C, Chronic / complications. Humans. Immunohistochemistry. Liver Cirrhosis / complications. Male. Middle Aged. Population Surveillance. Prognosis. Reoperation. Treatment Outcome


51. Tang W, Guo Q, Qu X, Inagaki Y, Seyama Y, Midorikawa Y, Gai R, Kokudo N, Sugawara Y, Nakata M, Makuuchi M: KL-6 mucin is a useful immunohistochemical marker for cholangiocarcinoma. Oncol Rep; 2007 Apr;17(4):737-41
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] KL-6 mucin is a useful immunohistochemical marker for cholangiocarcinoma.
  • This study aimed to clarify the clinical significance of the expression of KL-6 mucin, a type of MUC1, in primary liver cancer.
  • Tissue specimens were collected from 21 patients with cholangiocarcinoma (CC), 78 with hepatocellular carcinoma (HCC), and 12 with combined hepatocellular and cholangiocarcinoma (cHCC-CC).
  • Similar selectivity of KL-6 staining was also observed in the cHCC-CC specimens, and the cholangiocellular tissue could be clearly delineated by KL-6 staining.
  • In contrast, 79.5% of HCC specimens and 25.0% of cHCC-CC specimens were positive for Hep1 in the hepatocellular tissues, while none of the CC or cHCC-CC specimens were positive in the cholangiocellular tissues.
  • Staining for CK7 was positive in 95.2% of CC and 35.9% of HCC specimens, while 58.3 and 25.0% of cHCC-CC specimens displayed positivity for CK7 in the cholangiocellular and hepatocellular tissues, respectively.
  • [MeSH-major] Antigens, Neoplasm / analysis. Bile Duct Neoplasms / diagnosis. Biomarkers, Tumor / analysis. Cholangiocarcinoma / diagnosis. Mucins / analysis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Carcinoma, Hepatocellular / diagnosis. Carcinoma, Hepatocellular / pathology. Diagnosis, Differential. Female. Hepatocytes / immunology. Humans. Immunohistochemistry. Keratin-7 / analysis. Liver Neoplasms / diagnosis. Liver Neoplasms / pathology. Male. Middle Aged. Mucin-1

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17342308.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / Keratin-7; 0 / MUC1 protein, human; 0 / Mucin-1; 0 / Mucins
  •  go-up   go-down


52. Suksumek N, Leelawat K, Leelawat S, Russell B, Lek-Uthai U: TaqMan real-time PCR assay for specific detection of Opisthorchis viverrini DNA in Thai patients with hepatocellular carcinoma and cholangiocarcinoma. Exp Parasitol; 2008 Jun;119(2):217-24
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] TaqMan real-time PCR assay for specific detection of Opisthorchis viverrini DNA in Thai patients with hepatocellular carcinoma and cholangiocarcinoma.
  • The aim of this study was to develop TaqMan real-time PCR assay that detected Opisthorchis viverrini DNA from 18 normal and 18 tumor tissue specimens from Thai patients with hepatocellular carcinoma (HCC) and cholangiocarcinoma (CCA), who underwent liver resection from October 2005 to May 2006.
  • Control liver specimens were seven non-primary liver cancers.
  • [MeSH-major] Bile Duct Neoplasms / parasitology. Carcinoma, Hepatocellular / parasitology. Cholangiocarcinoma / parasitology. Liver Neoplasms / parasitology. Opisthorchiasis / diagnosis. Opisthorchis / isolation & purification
  • [MeSH-minor] Adult. Aged. Animals. Case-Control Studies. Computer Systems. DNA Probes. DNA, Helminth / isolation & purification. Female. Humans. Liver / parasitology. Male. Middle Aged. Polymerase Chain Reaction / methods. Risk Factors. Thailand / epidemiology

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18329641.001).
  • [ISSN] 1090-2449
  • [Journal-full-title] Experimental parasitology
  • [ISO-abbreviation] Exp. Parasitol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA Probes; 0 / DNA, Helminth
  •  go-up   go-down


53. Lee SG, Song GW, Hwang S, Ha TY, Moon DB, Jung DH, Kim KH, Ahn CS, Kim MH, Lee SK, Sung KB, Ko GY: Surgical treatment of hilar cholangiocarcinoma in the new era: the Asan experience. J Hepatobiliary Pancreat Sci; 2010 Jul;17(4):476-89
MedlinePlus Health Information. consumer health - Bile Duct Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgical treatment of hilar cholangiocarcinoma in the new era: the Asan experience.
  • BACKGROUND/PURPOSE: Both curative resection and minimized in-hospital mortality offer the only chance of long-term survival in patients with hilar cholangiocarcinoma.
  • The reported resectability rates for hilar cholangiocarcinoma have increased by virtue of combined major hepatectomy, but this procedure is technically demanding and still associated with a significant morbidity and mortality that must be carefully balanced against the chances of long-term survival.
  • METHODS: Between January 2001 and December 2008, 350 patients with hilar cholangiocarcinoma underwent exploration for the purpose of potentially curative resection, of whom 302 (86.3%) were resected in the Department of Hepato-Biliary Surgery and Liver Transplantation, Asan Medical Center, University of Ulsan College of Medicine.
  • Liver transplantation was not performed as primary treatment for hilar cholangiocarcinoma.
  • CONCLUSION: Preoperative biliary decompression and portal vein embolization enabled us to reduce in-hospital deaths associated with extended hepatectomy for hilar cholangiocarcinoma.
  • [MeSH-major] Bile Duct Neoplasms / surgery. Bile Ducts, Intrahepatic. Cholangiocarcinoma / surgery. Hepatectomy / methods
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Follow-Up Studies. Hospital Mortality / trends. Humans. Korea / epidemiology. Male. Middle Aged. Retrospective Studies. Survival Rate / trends. Time Factors. Treatment Outcome. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19851704.001).
  • [ISSN] 1868-6982
  • [Journal-full-title] Journal of hepato-biliary-pancreatic sciences
  • [ISO-abbreviation] J Hepatobiliary Pancreat Sci
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


54. Soejima Y, Ueda S, Sanefuji K, Kayashima H, Yoshizumi T, Ikegami T, Yamashita Y, Sugimachi K, Iguchi T, Taketomi A, Maehara Y: Sequential pancreaticoduodenectomy after living donor liver transplantation for cholangiocarcinoma. Am J Transplant; 2008 Oct;8(10):2158-62
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sequential pancreaticoduodenectomy after living donor liver transplantation for cholangiocarcinoma.
  • Liver transplantation (LT) for patients with primary sclerosing cholangitis (PSC) is often contraindicated due to concomitant occurrence of cholangiocarcinoma (CC).
  • [MeSH-major] Cholangiocarcinoma / therapy. Liver Neoplasms / therapy. Liver Transplantation / methods. Pancreaticoduodenectomy / methods
  • [MeSH-minor] Adult. Cell Differentiation. Follow-Up Studies. Humans. Liver / pathology. Living Donors. Male. Models, Anatomic. Neoplasm Invasiveness. Time Factors

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Liver Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18727703.001).
  • [ISSN] 1600-6143
  • [Journal-full-title] American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons
  • [ISO-abbreviation] Am. J. Transplant.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Denmark
  •  go-up   go-down


55. Zhang F, Chen XP, Zhang W, Dong HH, Xiang S, Zhang WG, Zhang BX: Combined hepatocellular cholangiocarcinoma originating from hepatic progenitor cells: immunohistochemical and double-fluorescence immunostaining evidence. Histopathology; 2008 Jan;52(2):224-32
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combined hepatocellular cholangiocarcinoma originating from hepatic progenitor cells: immunohistochemical and double-fluorescence immunostaining evidence.
  • AIMS: Combined hepatocellular cholangiocarcinoma (CHC) is a rare form of primary liver cancer, showing a mixture of hepatocellular and biliary features.
  • [MeSH-major] Bile Ducts, Intrahepatic / pathology. Carcinoma, Hepatocellular / pathology. Cholangiocarcinoma / pathology. Hepatocytes / pathology. Liver Neoplasms / pathology. Stem Cells / pathology
  • [MeSH-minor] Adult. Aged. Cell Transformation, Neoplastic / metabolism. Cell Transformation, Neoplastic / pathology. Female. Humans. Keratin-19 / metabolism. Keratin-7 / metabolism. Male. Middle Aged. Proto-Oncogene Proteins c-kit / metabolism. Receptor, PAR-1 / metabolism

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Stem Cells.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18184271.001).
  • [ISSN] 1365-2559
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Keratin-19; 0 / Keratin-7; 0 / Receptor, PAR-1; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit
  •  go-up   go-down


56. Heimbach JK, Gores GJ, Haddock MG, Alberts SR, Pedersen R, Kremers W, Nyberg SL, Ishitani MB, Rosen CB: Predictors of disease recurrence following neoadjuvant chemoradiotherapy and liver transplantation for unresectable perihilar cholangiocarcinoma. Transplantation; 2006 Dec 27;82(12):1703-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Predictors of disease recurrence following neoadjuvant chemoradiotherapy and liver transplantation for unresectable perihilar cholangiocarcinoma.
  • BACKGROUND: Sixty-five patients with unresectable hilar cholangiocarcinoma (CCA) have undergone orthotopic liver transplantation (OLT) after neoadjuvant chemoradiotherapy per a clinical care protocol developed in 1993.
  • Underlying primary sclerosing cholangitis, percutaneous biliary intubation, gender, and other time points for CA 19-9 were not associated with recurrence.
  • [MeSH-major] Bile Duct Neoplasms / therapy. Bile Ducts, Intrahepatic. CA-19-9 Antigen / blood. Cholangiocarcinoma / therapy. Liver Transplantation. Neoplasm Recurrence, Local / diagnosis
  • [MeSH-minor] Adult. Age Factors. Aged. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Neoadjuvant Therapy. Prognosis. Risk Factors


57. Prytz H, Keiding S, Björnsson E, Broomé U, Almer S, Castedal M, Munk OL, Swedish Internal Medicine Liver Club: Dynamic FDG-PET is useful for detection of cholangiocarcinoma in patients with PSC listed for liver transplantation. Hepatology; 2006 Dec;44(6):1572-80
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dynamic FDG-PET is useful for detection of cholangiocarcinoma in patients with PSC listed for liver transplantation.
  • Five to 15% of patients with primary sclerosing cholangitis (PSC) develop cholangiocarcinoma (CC) with a median survival of 5 to 7 months, an outcome not significantly improved by liver transplantation.
  • [MeSH-major] Cholangiocarcinoma / diagnosis. Cholangitis, Sclerosing / complications. Fluorodeoxyglucose F18. Positron-Emission Tomography / methods
  • [MeSH-minor] Adolescent. Adult. False Negative Reactions. False Positive Reactions. Female. Humans. Liver / pathology. Liver Transplantation. Male. Middle Aged. Prospective Studies

  • Genetic Alliance. consumer health - Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Liver Transpl. 2007 Apr;13(4):622-3 [17494129.001]
  • (PMID = 17133469.001).
  • [ISSN] 0270-9139
  • [Journal-full-title] Hepatology (Baltimore, Md.)
  • [ISO-abbreviation] Hepatology
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


58. Zhou NX, Huang ZQ, Zhang WZ, Huang XQ, Wang J, Liu R, Ji WB, Xiao M, Meng XF: [Surgical treatment of 402 consecutive cases for hilar cholangiocarcinoma: Chinese single center experience]. Zhonghua Wai Ke Za Zhi; 2006 Dec 1;44(23):1599-603
MedlinePlus Health Information. consumer health - Bile Duct Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Surgical treatment of 402 consecutive cases for hilar cholangiocarcinoma: Chinese single center experience].
  • OBJECTIVE: To analyze clinical typing, pathologic characteristics of hilar cholangiocarcinoma (HCCA) and surgical strategies and their effects on HCCA, and to explore the factors that influence the surgical outcomes and long-term survival.
  • Primary outcomes examined included clinical typing, pathologic characteristics, surgical procedures and follow-up results.
  • [MeSH-major] Bile Duct Neoplasms / surgery. Bile Ducts, Intrahepatic. Cholangiocarcinoma / surgery
  • [MeSH-minor] Adolescent. Adult. Aged. China. Female. Follow-Up Studies. Humans. Male. Middle Aged. Prognosis. Retrospective Studies. Survival Analysis. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17359686.001).
  • [ISSN] 0529-5815
  • [Journal-full-title] Zhonghua wai ke za zhi [Chinese journal of surgery]
  • [ISO-abbreviation] Zhonghua Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


59. Mantel HT, Rosen CB, Heimbach JK, Nyberg SL, Ishitani MB, Andrews JC, McKusick MA, Haddock MG, Alberts SR, Gores GJ: Vascular complications after orthotopic liver transplantation after neoadjuvant therapy for hilar cholangiocarcinoma. Liver Transpl; 2007 Oct;13(10):1372-81
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Vascular complications after orthotopic liver transplantation after neoadjuvant therapy for hilar cholangiocarcinoma.
  • Liver transplantation after neoadjuvant chemoradiotherapy has emerged as an effective treatment for patients with localized, node-negative, unresectable hilar cholangiocarcinoma (CCA) or CCA arising in the setting of primary sclerosing cholangitis (PSC).
  • [MeSH-major] Antineoplastic Agents / adverse effects. Bile Duct Neoplasms / therapy. Bile Ducts, Intrahepatic. Cholangiocarcinoma / therapy. Graft Occlusion, Vascular / etiology. Liver Transplantation / adverse effects
  • [MeSH-minor] Adult. Aged. Female. Graft Survival. Humans. Male. Middle Aged. Neoadjuvant Therapy. Postoperative Complications. Radiotherapy, Adjuvant / adverse effects. Treatment Outcome. Ultrasonography, Doppler, Duplex

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • MedlinePlus Health Information. consumer health - Liver Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2007 AASLD.
  • [CommentIn] Liver Transpl. 2007 Oct;13(10):1358-61 [17902140.001]
  • (PMID = 17427173.001).
  • [ISSN] 1527-6465
  • [Journal-full-title] Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society
  • [ISO-abbreviation] Liver Transpl.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


60. Lei JY, Bourne PA, diSant'Agnese PA, Huang J: Cytoplasmic staining of TTF-1 in the differential diagnosis of hepatocellular carcinoma vs cholangiocarcinoma and metastatic carcinoma of the liver. Am J Clin Pathol; 2006 Apr;125(4):519-25
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytoplasmic staining of TTF-1 in the differential diagnosis of hepatocellular carcinoma vs cholangiocarcinoma and metastatic carcinoma of the liver.
  • The cytoplasmic staining of thyroid transcription factor (TTF)-1 was analyzed in 86 liver resection specimens, including 40 hepatocellular carcinoma (HCC), 4 metastatic HCC, 20 cholangiocarcinoma, 2 combined hepatocellular-cholangiocarcinoma (CHC), and 20 metastatic carcinoma (MC) specimens with immunohistochemical stains to TTF-1, cytokeratin (CK)19, hepatocyte paraffin 1, alpha-fetoprotein, polyclonal carcinoembryonic antigen, CK7, and CK20.
  • The results suggest TTF-1 cytoplasmic staining, together with CK19, might serve as a useful marker for the diagnosis of primary and metastatic HCC and for the differential diagnosis of HCC from cholangiocarcinoma and MC.
  • [MeSH-major] Carcinoma, Hepatocellular / diagnosis. Cholangiocarcinoma / diagnosis. Cytoplasm / metabolism. Liver Neoplasms / diagnosis. Nuclear Proteins / metabolism. Transcription Factors / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / analysis. Diagnosis, Differential. Female. Humans. Immunohistochemistry. Keratins / metabolism. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16627262.001).
  • [ISSN] 0002-9173
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Nuclear Proteins; 0 / Transcription Factors; 0 / thyroid nuclear factor 1; 68238-35-7 / Keratins
  •  go-up   go-down


61. Taweevisit M, Chirakalwasan N, Pumsuk U, Keelawat S, Shuangshoti S: Metastatic adenocarcinoma to the cervical lymph node: a significant proportion of cholangiocarcinoma in Thai patients. Asian Pac J Cancer Prev; 2008 Jan-Mar;9(1):39-41
MedlinePlus Health Information. consumer health - Bile Duct Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic adenocarcinoma to the cervical lymph node: a significant proportion of cholangiocarcinoma in Thai patients.
  • OBJECTIVE: To determine distribution of the primary site of metastatic adenocarcinoma to the cervical lymph node in Thai population with histological correlation.
  • RESULTS: Thyroid gland (papillary carcinoma) was the commonest source of tumor (41%), followed by lung (25%), bile duct (17%) and breast (7%).
  • Metastatic cholangiocarcinoma typically produced distinct glandular pattern, and frequently involved the right supraclavicular lymph node.
  • Brush border of the gland-forming tumor cells was a consistent finding in metastatic cholangiocarcinoma, with 100% sensitivity and 97% specificity.
  • CONCLUSIONS: Cholangiocarcinoma represents a significant portion of primary tumor in Thai patients with cervical nodal metastasis.
  • This figure may hold true for countries where bile duct malignancy is endemic, and may be of clinical usefulness in identification of primary cancer.
  • [MeSH-major] Adenocarcinoma / secondary. Bile Duct Neoplasms / pathology. Bile Ducts, Intrahepatic / pathology. Cholangiocarcinoma / secondary. Lymph Nodes / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Lung Neoplasms / pathology. Lymphatic Metastasis. Male. Middle Aged. Prognosis. Retrospective Studies. Thailand. Thyroid Neoplasms / pathology. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18439070.001).
  • [ISSN] 2476-762X
  • [Journal-full-title] Asian Pacific journal of cancer prevention : APJCP
  • [ISO-abbreviation] Asian Pac. J. Cancer Prev.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Thailand
  •  go-up   go-down


62. Becker NS, Rodriguez JA, Barshes NR, O'Mahony CA, Goss JA, Aloia TA: Outcomes analysis for 280 patients with cholangiocarcinoma treated with liver transplantation over an 18-year period. J Gastrointest Surg; 2008 Jan;12(1):117-22
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcomes analysis for 280 patients with cholangiocarcinoma treated with liver transplantation over an 18-year period.
  • Cholangiocarcinoma is an aggressive malignancy with 5-year survival rates<15%.
  • Two hundred eighty patients with cholangiocarcinoma treated with OLT from 1987 to 2005 were identified in The United Network for Organ Sharing database.
  • Study variables associated with improved survivals included diagnosis of cholangiocarcinoma pre-OLT [5-year overall survival (OS): 68 vs. 20% for patients with incidental diagnoses at the time of OLT, p<0.001] and OLT after 1993 (5-year OS: 45 vs. 30% pre-1994, p<0.01).
  • In contrast, the diagnosis of concomitant primary sclerosing cholangitis did not impact survivals (5-year OS: 41 vs. 50% without primary sclerosing cholangitis, p=0.402).
  • Selected cholangiocarcinoma patients treated with OLT experience a survival benefit.
  • These data support the continued development of multimodality cholangiocarcinoma treatment protocols that include OLT.
  • [MeSH-major] Bile Duct Neoplasms / surgery. Bile Ducts, Intrahepatic. Cholangiocarcinoma / surgery. Liver Transplantation / methods
  • [MeSH-minor] Adolescent. Adult. Aged. Female. Follow-Up Studies. Graft Survival. Humans. Male. Middle Aged. Prognosis. Retrospective Studies. Survival Rate / trends. Time Factors. United States / epidemiology

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • MedlinePlus Health Information. consumer health - Liver Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17963015.001).
  • [ISSN] 1091-255X
  • [Journal-full-title] Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  • [ISO-abbreviation] J. Gastrointest. Surg.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Multicenter Study
  • [Publication-country] United States
  •  go-up   go-down


63. Vernez M, Hutter P, Monnerat C, Halkic N, Gugerli O, Bouzourene H: A case of Muir-Torre syndrome associated with mucinous hepatic cholangiocarcinoma and a novel germline mutation of the MSH2 gene. Fam Cancer; 2007;6(1):141-5
Hazardous Substances Data Bank. L-SERINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of Muir-Torre syndrome associated with mucinous hepatic cholangiocarcinoma and a novel germline mutation of the MSH2 gene.
  • We report a case of Muir-Torre syndrome associated with intrahepatic cholangiocarcinoma, a location not previously described, and associated with a novel missense mutation of the MSH2 gene (c.2026T > C), predicted to disrupt the function of the gene.
  • [MeSH-major] Cholangiocarcinoma / genetics. Cholangiocarcinoma / secondary. Germ-Line Mutation. Liver Neoplasms / genetics. MutS Homolog 2 Protein / deficiency. Neoplasms, Multiple Primary / genetics. Neoplastic Syndromes, Hereditary / genetics. Skin Neoplasms / genetics
  • [MeSH-minor] Adenocarcinoma, Mucinous / genetics. Adenocarcinoma, Mucinous / surgery. Adenoma / genetics. Adenoma / surgery. Adult. Brain Neoplasms / genetics. Brain Neoplasms / secondary. Brain Neoplasms / surgery. Carcinoma / genetics. Carcinoma / surgery. Colorectal Neoplasms, Hereditary Nonpolyposis / genetics. Colorectal Neoplasms, Hereditary Nonpolyposis / surgery. DNA Mutational Analysis. DNA Probes. DNA-Binding Proteins. Endometrial Neoplasms / surgery. Female. Humans. Microsatellite Instability. Mutation, Missense. Polyps / surgery. Proline / genetics. Sebaceous Gland Neoplasms / genetics. Sebaceous Gland Neoplasms / surgery. Serine / genetics. Syndrome

  • Genetic Alliance. consumer health - Keratoacanthoma.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. (L)-PROLINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17051350.001).
  • [ISSN] 1389-9600
  • [Journal-full-title] Familial cancer
  • [ISO-abbreviation] Fam. Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / DNA Probes; 0 / DNA-Binding Proteins; 452VLY9402 / Serine; 9DLQ4CIU6V / Proline; EC 3.6.1.3 / MutS Homolog 2 Protein
  •  go-up   go-down


64. Chantajitr S, Wilasrusmee C, Lertsitichai P, Phromsopha N: Combined hepatocellular and cholangiocarcinoma: clinical features and prognostic study in a Thai population. J Hepatobiliary Pancreat Surg; 2006;13(6):537-42
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combined hepatocellular and cholangiocarcinoma: clinical features and prognostic study in a Thai population.
  • BACKGROUND/PURPOSE: Combined hepatocellular and cholangiocarcinoma (HCC-CC) is an uncommon subtype of primary liver cancer, the clinicopathological features of which have rarely been reported in detail.
  • The presence of cholangiocellular differentiation appeared to worsen the prognosis when compared with pure HCC, although this difference did not reach statistical significance.
  • [MeSH-major] Bile Duct Neoplasms / diagnosis. Bile Ducts, Intrahepatic. Carcinoma, Hepatocellular / diagnosis. Cholangiocarcinoma / diagnosis. Liver Neoplasms / diagnosis
  • [MeSH-minor] Adult. Aged. Female. Humans. Male. Middle Aged. Prognosis. Retrospective Studies. Survival Analysis. Thailand

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17139428.001).
  • [ISSN] 0944-1166
  • [Journal-full-title] Journal of hepato-biliary-pancreatic surgery
  • [ISO-abbreviation] J Hepatobiliary Pancreat Surg
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


65. Nakagawa T, Kamiyama T, Kurauchi N, Matsushita M, Nakanishi K, Kamachi H, Kudo T, Todo S: Number of lymph node metastases is a significant prognostic factor in intrahepatic cholangiocarcinoma. World J Surg; 2005 Jun;29(6):728-33
MedlinePlus Health Information. consumer health - Bile Duct Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Number of lymph node metastases is a significant prognostic factor in intrahepatic cholangiocarcinoma.
  • Intrahepatic cholangiocarcinoma (IHCC) is a rare primary hepatic tumor.
  • [MeSH-major] Bile Duct Neoplasms / mortality. Bile Duct Neoplasms / pathology. Bile Ducts, Intrahepatic. Cholangiocarcinoma / mortality. Cholangiocarcinoma / secondary
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Follow-Up Studies. Hepatectomy. Humans. Lymph Node Excision. Lymphatic Metastasis. Male. Middle Aged. Retrospective Studies. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Intrahepatic cholangiocarcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15880276.001).
  • [ISSN] 0364-2313
  • [Journal-full-title] World journal of surgery
  • [ISO-abbreviation] World J Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


66. Wu Y, Johlin FC, Rayhill SC, Jensen CS, Xie J, Cohen MB, Mitros FA: Long-term, tumor-free survival after radiotherapy combining hepatectomy-Whipple en bloc and orthotopic liver transplantation for early-stage hilar cholangiocarcinoma. Liver Transpl; 2008 Mar;14(3):279-86
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term, tumor-free survival after radiotherapy combining hepatectomy-Whipple en bloc and orthotopic liver transplantation for early-stage hilar cholangiocarcinoma.
  • This retrospective study reviews our experience in surveillance and early detection of cholangiocarcinoma (CC) and in using en bloc total hepatectomy-pancreaticoduodenectomy-orthotopic liver transplantation (OLT-Whipple) to achieve complete eradication of early-stage CC complicating primary sclerosing cholangitis (PSC).
  • [MeSH-major] Bile Duct Neoplasms / radiotherapy. Bile Duct Neoplasms / surgery. Bile Ducts, Intrahepatic. Cholangiocarcinoma / radiotherapy. Cholangiocarcinoma / surgery. Hepatectomy / methods. Liver Transplantation / methods
  • [MeSH-minor] Adolescent. Adult. Cholangiopancreatography, Endoscopic Retrograde. Cholangitis, Sclerosing / complications. Combined Modality Therapy. Disease-Free Survival. Humans. Middle Aged. Pancreaticoduodenectomy / methods. Retrospective Studies. Time Factors. Treatment Outcome

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • MedlinePlus Health Information. consumer health - Liver Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18306329.001).
  • [ISSN] 1527-6473
  • [Journal-full-title] Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society
  • [ISO-abbreviation] Liver Transpl.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


67. Wu YM, Johlin FC, Rayhill SC, Jensen CS, Jin X, Mitros FA: [Long-term, tumor-free survival after radiotherapy combining hepatectomy-Whipple en bloc and orthotopic liver transplantation for early-stage hilar cholangiocarcinoma]. Zhonghua Wai Ke Za Zhi; 2009 Aug 1;47(15):1155-61
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Long-term, tumor-free survival after radiotherapy combining hepatectomy-Whipple en bloc and orthotopic liver transplantation for early-stage hilar cholangiocarcinoma].
  • OBJECTIVE: To report the experience in surveillance and early detection of cholangiocarcinoma (CC) and in using en bloc total hepatectomy-pancreaticoduodenectomy-orthotopic liver transplantation (OLT-Whipple) to achieve complete eradication of early-stage CC complicating primary sclerosing cholangitis (PSC).
  • [MeSH-major] Bile Duct Neoplasms / surgery. Bile Ducts, Intrahepatic. Cholangiocarcinoma / surgery
  • [MeSH-minor] Adolescent. Adult. Disease-Free Survival. Early Diagnosis. Female. Follow-Up Studies. Hepatectomy. Humans. Liver Transplantation. Male. Mass Screening. Middle Aged. Pancreaticoduodenectomy. Retrospective Studies

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20021907.001).
  • [ISSN] 0529-5815
  • [Journal-full-title] Zhonghua wai ke za zhi [Chinese journal of surgery]
  • [ISO-abbreviation] Zhonghua Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


68. Nagaoka S, Itano S, Ishibashi M, Torimura T, Baba K, Akiyoshi J, Kurogi J, Matsugaki S, Inoue K, Tajiri N, Takada A, Ando E, Kuromatsu R, Kaida H, Kurogi M, Koga H, Kumashiro R, Hayabuchi N, Kojiro M, Sata M: Value of fusing PET plus CT images in hepatocellular carcinoma and combined hepatocellular and cholangiocarcinoma patients with extrahepatic metastases: preliminary findings. Liver Int; 2006 Sep;26(7):781-8
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Value of fusing PET plus CT images in hepatocellular carcinoma and combined hepatocellular and cholangiocarcinoma patients with extrahepatic metastases: preliminary findings.
  • BACKGROUND/AIMS: This study aimed to evaluate the usefulness of (18)F-fluoro-2-deoxy-d-glucose positron emission tomography (PET) and PET plus computed tomography (CT) fusion images for the detection of extrahepatic metastases of hepatocellular carcinoma (HCC) and combined hepatocellular and cholangiocarcinoma (combined HCC/CC).
  • [MeSH-major] Bile Duct Neoplasms / radionuclide imaging. Bile Ducts, Intrahepatic / radionuclide imaging. Carcinoma, Hepatocellular / radionuclide imaging. Cholangiocarcinoma / radionuclide imaging. Liver Neoplasms / radionuclide imaging
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Neoplasm Metastasis. Neoplasms, Multiple Primary / pathology. Neoplasms, Multiple Primary / radiography. Positron-Emission Tomography. Predictive Value of Tests. Sensitivity and Specificity. Tomography, Emission-Computed

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16911459.001).
  • [ISSN] 1478-3223
  • [Journal-full-title] Liver international : official journal of the International Association for the Study of the Liver
  • [ISO-abbreviation] Liver Int.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] England
  •  go-up   go-down


69. Nakanuma S, Tajima H, Okamoto K, Hayashi H, Nakagawara H, Onishi I, Takamura H, Kitagawa H, Fushida S, Tani T, Fujimura T, Kayahara M, Ohta T, Wakayama T, Iseki S, Harada S: Tumor-derived trypsin enhances proliferation of intrahepatic cholangiocarcinoma cells by activating protease-activated receptor-2. Int J Oncol; 2010 Apr;36(4):793-800
MedlinePlus Health Information. consumer health - Bile Duct Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumor-derived trypsin enhances proliferation of intrahepatic cholangiocarcinoma cells by activating protease-activated receptor-2.
  • In primary malignant liver tumors, trypsinogen-immunoreactivity was present in 70% of intrahepatic cholangiocarcinoma (ICC) specimens, but absent in hepatocellular carcinoma (HCC) specimens.
  • [MeSH-major] Bile Duct Neoplasms / enzymology. Bile Ducts, Intrahepatic / enzymology. Cell Proliferation. Cholangiocarcinoma / enzymology. Receptor, PAR-2 / metabolism. Trypsin / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Carcinoma, Hepatocellular / enzymology. Carcinoma, Hepatocellular / pathology. Culture Media, Serum-Free / metabolism. Dose-Response Relationship, Drug. Female. Fibroblasts / enzymology. Fibroblasts / pathology. Gabexate / pharmacology. Gene Expression Regulation, Enzymologic. Gene Expression Regulation, Neoplastic. Hep G2 Cells. Humans. Liver Neoplasms / enzymology. Liver Neoplasms / pathology. Male. Middle Aged. RNA, Messenger / metabolism. Serine Proteinase Inhibitors / pharmacology

  • Genetic Alliance. consumer health - Intrahepatic cholangiocarcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20198321.001).
  • [ISSN] 1791-2423
  • [Journal-full-title] International journal of oncology
  • [ISO-abbreviation] Int. J. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Culture Media, Serum-Free; 0 / RNA, Messenger; 0 / Receptor, PAR-2; 0 / Serine Proteinase Inhibitors; 4V7M9137X9 / Gabexate; EC 3.4.21.4 / PRSS1 protein, human; EC 3.4.21.4 / Trypsin
  •  go-up   go-down


70. Kim JY, Kim MH, Lee TY, Hwang CY, Kim JS, Yun SC, Lee SS, Seo DW, Lee SK: Clinical role of 18F-FDG PET-CT in suspected and potentially operable cholangiocarcinoma: a prospective study compared with conventional imaging. Am J Gastroenterol; 2008 May;103(5):1145-51
MedlinePlus Health Information. consumer health - CT Scans.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical role of 18F-FDG PET-CT in suspected and potentially operable cholangiocarcinoma: a prospective study compared with conventional imaging.
  • OBJECTIVES: This study was conducted to evaluate the clinical role of integrated positron emission and computed tomography (PET-CT) in patients with suspected and potentially operable cholangiocarcinoma.
  • METHODS: Between October 2005 and May 2007, 123 patients with suspected cholangiocarcinoma were enrolled in this study after diagnostic workup, including biliary dynamic computed tomography (CT) and magnetic resonance imaging/magnetic resonance cholangiopancreatography (MRI/MRCP) with magnetic resonance (MR) angiography.
  • Patients with overt unresectable cholangiocarcinoma or gallbladder cancer diagnosed via conventional imaging were excluded.
  • RESULTS: The overall values for sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and accuracy of PET-CT in primary tumor detection were 84.0%, 79.3%, 92.9%, 60.5%, and 82.9%, respectively.
  • PET-CT demonstrated no statistically significant advantage over CT and MRI/MRCP in the diagnosis of primary tumor.
  • According to different morphologic characteristics of cholangiocarcinoma, PET-CT showed no significant difference in detecting those of mass-forming, periductal-infiltrating, and intraductal-growing types.
  • Additional use of PET-CT for assessing resectability correctly showed different results from those determined by conventional imaging in 15 (15.9%) of 94 patients with cholangiocarcinoma.
  • CONCLUSIONS: PET-CT improved the accuracy of preoperative staging in patients with cholangiocarcinoma planning to undergo curative resection.
  • [MeSH-major] Bile Duct Neoplasms / radionuclide imaging. Bile Ducts, Extrahepatic / radionuclide imaging. Bile Ducts, Intrahepatic / radionuclide imaging. Cholangiocarcinoma / radionuclide imaging. Fluorodeoxyglucose F18. Image Processing, Computer-Assisted. Positron-Emission Tomography. Tomography, X-Ray Computed
  • [MeSH-minor] Adult. Aged. Biopsy. Cholangiopancreatography, Magnetic Resonance. Female. Humans. Lymphatic Metastasis / pathology. Lymphatic Metastasis / radionuclide imaging. Magnetic Resonance Angiography. Male. Middle Aged. Neoplasm Staging. Prospective Studies. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18177454.001).
  • [ISSN] 1572-0241
  • [Journal-full-title] The American journal of gastroenterology
  • [ISO-abbreviation] Am. J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


71. Okamura Y, Harada A, Maeda A, Fujioka A, Horiba T, Ishigure K, Hirai A, Ito Y, Uesaka K: Carcinomatous meningitis secondary to cholangiocarcinoma without other systemic metastasis. J Hepatobiliary Pancreat Surg; 2008;15(2):237-9
MedlinePlus Health Information. consumer health - Meningitis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Carcinomatous meningitis secondary to cholangiocarcinoma without other systemic metastasis.
  • It occurs in about 5% of all adult cancer patients, though autopsies may double this number.
  • The primary tumors that frequently cause carcinomatous meningitis include lung cancer, breast cancer, leukemia, lymphoma, and melanoma.
  • Carcinomatous meningitis secondary to primary tumors in the gastrointestinal tract is clinically infrequent.
  • In this report, we describe a 73-year-old man with lower bile duct cancer, who developed carcinomatous meningitis following surgical resection of the primary cancer.
  • To our knowledge, this is the third case of carcinomatous meningitis secondary to cholangiocarcinoma described in the literature so far.
  • [MeSH-major] Bile Duct Neoplasms / pathology. Bile Ducts, Intrahepatic. Cholangiocarcinoma / secondary. Meningeal Neoplasms / secondary. Meningitis / etiology

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18392723.001).
  • [ISSN] 0944-1166
  • [Journal-full-title] Journal of hepato-biliary-pancreatic surgery
  • [ISO-abbreviation] J Hepatobiliary Pancreat Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


72. Zhou YM, Yin ZF, Yang JM, Li B, Shao WY, Xu F, Wang YL, Li DQ: Risk factors for intrahepatic cholangiocarcinoma: a case-control study in China. World J Gastroenterol; 2008 Jan 28;14(4):632-5
MedlinePlus Health Information. consumer health - Bile Duct Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Risk factors for intrahepatic cholangiocarcinoma: a case-control study in China.
  • AIM: To carry out a hospital-based case-control study to investigate risk factors for intrahepatic cholangiocarcinoma (ICC) in China.
  • The presence of diabetes mellitus, hypertension, hepatolithiasis, primary sclerosing cholangitis, liver fluke infection (Clonorchis sinensis), was investigated through clinical records.
  • [MeSH-major] Bile Duct Neoplasms / epidemiology. Bile Ducts, Intrahepatic. Cholangiocarcinoma / epidemiology. Hepatitis B, Chronic / epidemiology
  • [MeSH-minor] Adult. Aged. Case-Control Studies. China / epidemiology. Endemic Diseases / statistics & numerical data. Female. Humans. Male. Middle Aged. Prevalence. Risk Factors

  • Genetic Alliance. consumer health - Intrahepatic cholangiocarcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1991 Nov 15;68(10):2217-23 [1655206.001]
  • [Cites] Zhonghua Gan Zang Bing Za Zhi. 2005 Dec;13(12):881-91 [16491521.001]
  • [Cites] Chin Med J (Engl). 1992 Mar;105(3):209-11 [1395840.001]
  • [Cites] Hepatology. 1995 Nov;22(5):1404-8 [7590655.001]
  • [Cites] Int J Epidemiol. 1996 Oct;25(5):933-40 [8921477.001]
  • [Cites] Hepatology. 1997 Feb;25(2):463-9 [9021965.001]
  • [Cites] J Gastroenterol Hepatol. 1999 Dec;14(12):1144-9 [10634149.001]
  • [Cites] Cancer. 2000 Jun 1;88(11):2471-7 [10861422.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 2000;7(6):542-50 [11180885.001]
  • [Cites] Intern Med. 2001 May;40(5):382-5 [11393406.001]
  • [Cites] Cancer Causes Control. 2001 Dec;12(10):959-64 [11808716.001]
  • [Cites] J Hepatol. 2002 Mar;36(3):321-7 [11867174.001]
  • [Cites] Hepatology. 2002 Aug;36(2):439-50 [12143054.001]
  • [Cites] Clin Gastroenterol Hepatol. 2003 Jul;1(4):285-96 [15017670.001]
  • [Cites] Lab Invest. 2004 May;84(5):629-38 [15048136.001]
  • [Cites] Semin Liver Dis. 2004 May;24(2):115-25 [15192785.001]
  • [Cites] Cancer Sci. 2004 Jul;95(7):592-5 [15245596.001]
  • [Cites] World J Gastroenterol. 2004 Aug 1;10(15):2259-62 [15259077.001]
  • [Cites] Proc Natl Acad Sci U S A. 1983 Nov;80(21):6685-8 [6579553.001]
  • [Cites] Int J Cancer. 1991 May 30;48(3):323-8 [1645697.001]
  • [Cites] Cancer Res. 1991 Sep 15;51(18):4971-7 [1654208.001]
  • [Cites] Br J Surg. 1997 Jul;84(7):969-73 [9240138.001]
  • [Cites] Hum Pathol. 1998 Feb;29(2):175-80 [9490278.001]
  • [Cites] Zhonghua Liu Xing Bing Xue Za Zhi. 1998 Jun;19(3):134-7 [10322727.001]
  • [Cites] Hum Pathol. 2004 Dec;35(12):1505-14 [15619210.001]
  • [Cites] Gastroenterology. 2005 Mar;128(3):620-6 [15765398.001]
  • [Cites] Lancet. 2005 Oct 8;366(9493):1303-14 [16214602.001]
  • [Cites] J Lab Clin Med. 2006 Feb;147(2):58-66 [16459163.001]
  • [Cites] J Clin Virol. 2005 Dec;34 Suppl 1:S75-8 [16461228.001]
  • [Cites] Virchows Arch A Pathol Anat Histopathol. 1992;420(4):327-35 [1348889.001]
  • (PMID = 18203300.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Other-IDs] NLM/ PMC2681159
  •  go-up   go-down


73. Kim HJ, Kim AY, Hong SS, Kim MH, Byun JH, Won HJ, Shin YM, Kim PN, Ha HK, Lee MG: Biliary ductal evaluation of hilar cholangiocarcinoma: three-dimensional direct multi-detector row CT cholangiographic findings versus surgical and pathologic results--feasibility study. Radiology; 2006 Jan;238(1):300-8
MedlinePlus Health Information. consumer health - CT Scans.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Biliary ductal evaluation of hilar cholangiocarcinoma: three-dimensional direct multi-detector row CT cholangiographic findings versus surgical and pathologic results--feasibility study.
  • The study was conducted, with institutional review board approval and informed patient consent, to assess the feasibility and diagnostic effectiveness of three-dimensional direct multi-detector row computed tomographic (CT) cholangiography for determining the extent of bile duct invasion by hilar cholangiocarcinoma.
  • Eleven patients underwent contrast material-enhanced direct multi-detector row CT cholangiography of the primary and secondary biliary confluence levels and then surgical resection.
  • CT cholangiography enabled a correct diagnosis of the extent of ductal involvement at all 11 primary confluence levels and at 18 of the 19 secondary confluence levels.
  • Three secondary confluences, which could not be analyzed owing to nonopacification or poor opacification, proved to be involved by hilar cholangiocarcinoma.
  • The authors conclude that three-dimensional direct multi-detector row CT cholangiography is accurate and feasible for defining the extent of ductal invasion by hilar cholangiocarcinoma, especially in patients with preliminary biliary drainage.
  • [MeSH-major] Bile Duct Neoplasms / radiography. Bile Ducts, Intrahepatic. Cholangiocarcinoma / radiography. Cholangiography / methods. Tomography, X-Ray Computed
  • [MeSH-minor] Adult. Aged. Contrast Media. Feasibility Studies. Female. Humans. Image Processing, Computer-Assisted. Imaging, Three-Dimensional. Male. Middle Aged. Predictive Value of Tests. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] RSNA, 2005.
  • (PMID = 16304092.001).
  • [ISSN] 0033-8419
  • [Journal-full-title] Radiology
  • [ISO-abbreviation] Radiology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contrast Media
  •  go-up   go-down


74. John AR, Haghighi KS, Taniere P, Esmat ME, Tan YM, Bramhall SR: Is a raised CA 19-9 level diagnostic for a cholangiocarcinoma in patients with no history of sclerosing cholangitis ? Dig Surg; 2006;23(5-6):319-24
MedlinePlus Health Information. consumer health - Bile Duct Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Is a raised CA 19-9 level diagnostic for a cholangiocarcinoma in patients with no history of sclerosing cholangitis ?
  • BACKGROUND/AIM: A cholangiocarcinoma, the second most common primary hepatic malignancy, can present with diagnostic dilemmas.
  • The aim of this study is to assess the role of CA 19-9 in patients with a cholangiocarcinoma without primary sclerosing cholangitis.
  • RESULTS: Sensitivity and specificity of CA 19-9 in the diagnosis of a cholangiocarcinoma were 77.9 and 76.3%, respectively, when using a cut-off value of 35 kU/l, while sensitivity and specificity were 67.5 and 86.8%, respectively, when the cut-off value was raised to 100 kU/l.
  • CONCLUSIONS: This study demonstrates that CA 19-9 is a useful adjunct in the diagnosis of cholangiocarcinomas without primary sclerosing cholangitis, especially in the diagnosis of peripheral cholangiocarcinomas.
  • [MeSH-major] Bile Duct Neoplasms / blood. Bile Ducts, Intrahepatic. CA-19-9 Antigen / blood. Cholangiocarcinoma / blood
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / blood. Biopsy. Cholangitis, Sclerosing. Humans. Middle Aged. Prospective Studies. Sensitivity and Specificity

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2006 S. Karger AG, Basel.
  • (PMID = 17170527.001).
  • [ISSN] 0253-4886
  • [Journal-full-title] Digestive surgery
  • [ISO-abbreviation] Dig Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CA-19-9 Antigen
  •  go-up   go-down


75. Tang D, Nagano H, Nakamura M, Wada H, Marubashi S, Miyamoto A, Takeda Y, Umeshita K, Dono K, Monden M: Clinical and pathological features of Allen's type C classification of resected combined hepatocellular and cholangiocarcinoma: a comparative study with hepatocellular carcinoma and cholangiocellular carcinoma. J Gastrointest Surg; 2006 Jul-Aug;10(7):987-98
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical and pathological features of Allen's type C classification of resected combined hepatocellular and cholangiocarcinoma: a comparative study with hepatocellular carcinoma and cholangiocellular carcinoma.
  • The clinical features of Allen's type C of combined hepatocellular and cholangiocarcinoma (cHCC-CC) are not well known.
  • In this study, we aim to define the clinicopathologic features of cHCC-CC and to evaluate the preoperative diagnosis and surgical treatment results in comparison with those of hepatocellular carcinoma (HCC) and cholangiocellular carcinoma (CCC).
  • [MeSH-major] Bile Duct Neoplasms / pathology. Bile Duct Neoplasms / surgery. Bile Ducts, Intrahepatic. Carcinoma, Hepatocellular / pathology. Carcinoma, Hepatocellular / surgery. Cholangiocarcinoma / pathology. Cholangiocarcinoma / surgery. Liver Neoplasms / pathology. Liver Neoplasms / surgery. Neoplasms, Multiple Primary / pathology. Neoplasms, Multiple Primary / surgery
  • [MeSH-minor] Adult. Aged. Female. Hepatectomy. Humans. Immunohistochemistry. Male. Middle Aged. Retrospective Studies. Survival Rate

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16843869.001).
  • [ISSN] 1091-255X
  • [Journal-full-title] Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  • [ISO-abbreviation] J. Gastrointest. Surg.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


76. Chaudhary HB, Bhanot P, Logroño R: Phenotypic diversity of intrahepatic and extrahepatic cholangiocarcinoma on aspiration cytology and core needle biopsy: case series and review of the literature. Cancer; 2005 Aug 25;105(4):220-8
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phenotypic diversity of intrahepatic and extrahepatic cholangiocarcinoma on aspiration cytology and core needle biopsy: case series and review of the literature.
  • BACKGROUND: Cholangiocarcinoma (CC) represents approximately 10% of primary liver malignancies and can mimic metastatic adenocarcinoma.
  • [MeSH-major] Bile Duct Neoplasms / pathology. Bile Ducts, Extrahepatic / pathology. Bile Ducts, Intrahepatic / pathology. Cholangiocarcinoma / pathology. Liver Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Biopsy, Fine-Needle. Diagnosis, Differential. Female. Humans. Male. Middle Aged. Phenotype. Retrospective Studies

  • Genetic Alliance. consumer health - Intrahepatic cholangiocarcinoma.
  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2005 American Cancer Society.
  • (PMID = 15952192.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


77. Zhang C, Tu Z, Du S, Wang Y, Wang Q: Expression of matrix metalloproteinase 2 and extracellular matrix metalloproteinase inducer are unfavorable postoperative prognostic factors in intrahepatic cholangiocarcinoma. Pathol Oncol Res; 2010 Mar;16(1):47-53
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of matrix metalloproteinase 2 and extracellular matrix metalloproteinase inducer are unfavorable postoperative prognostic factors in intrahepatic cholangiocarcinoma.
  • Many investigators have indicated that overexpression and amplification of matrix metalloproteinase 2 (MMP-2) and extracellular matrix metalloproteinase inducer (EMMPRIN) are independent prognostic factors for primary tumors.
  • We studied expression of them in tissues from intrahepatic cholangiocarcinoma (IHCCA) and normal bile ducts, and discussed the occurrence and development of IHCCA.
  • MMP-2 and EMMPRIN expression in primary tumor predicts an unfavorable prognosis in IHCCA, suggesting a crucial role of the two markers in progression of human IHCCA.
  • [MeSH-major] Antigens, CD147 / biosynthesis. Bile Duct Neoplasms / metabolism. Bile Ducts, Intrahepatic / metabolism. Cholangiocarcinoma / metabolism. Matrix Metalloproteinase 2 / biosynthesis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / analysis. Female. Humans. Immunohistochemistry. Kaplan-Meier Estimate. Male. Middle Aged. Neoplasm Staging. Prognosis

  • Genetic Alliance. consumer health - Intrahepatic cholangiocarcinoma.
  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19629755.001).
  • [ISSN] 1532-2807
  • [Journal-full-title] Pathology oncology research : POR
  • [ISO-abbreviation] Pathol. Oncol. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / BSG protein, human; 0 / Biomarkers, Tumor; 136894-56-9 / Antigens, CD147; EC 3.4.24.24 / Matrix Metalloproteinase 2
  •  go-up   go-down


78. Man XB, Tang L, Zhang BH, Li SJ, Qiu XH, Wu MC, Wang HY: Upregulation of Glypican-3 expression in hepatocellular carcinoma but downregulation in cholangiocarcinoma indicates its differential diagnosis value in primary liver cancers. Liver Int; 2005 Oct;25(5):962-6
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Upregulation of Glypican-3 expression in hepatocellular carcinoma but downregulation in cholangiocarcinoma indicates its differential diagnosis value in primary liver cancers.
  • BACKGROUND/AIM: Expression alteration of Glypican-3 (GPC3) is associated with several malignancies and has been identified as an overexpressed gene in hepatocellular carcinoma (HCC).
  • [MeSH-major] Bile Duct Neoplasms / metabolism. Carcinoma, Hepatocellular / metabolism. Cholangiocarcinoma / metabolism. Liver Neoplasms / metabolism. Membrane Proteins / genetics. Neoplasm Proteins / genetics
  • [MeSH-minor] Adult. Aged. Bile Ducts, Intrahepatic. Diagnosis, Differential. Female. Gallbladder Neoplasms / diagnosis. Gallbladder Neoplasms / metabolism. Gene Expression Regulation, Neoplastic. Glypicans. Humans. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16162153.001).
  • [ISSN] 1478-3223
  • [Journal-full-title] Liver international : official journal of the International Association for the Study of the Liver
  • [ISO-abbreviation] Liver Int.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / GPC3 protein, human; 0 / Glypicans; 0 / Membrane Proteins; 0 / Neoplasm Proteins
  •  go-up   go-down


79. Tanaka M, Tanaka H, Tsukuma H, Ioka A, Oshima A, Nakahara T: Risk factors for intrahepatic cholangiocarcinoma: a possible role of hepatitis B virus. J Viral Hepat; 2010 Oct;17(10):742-8
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Risk factors for intrahepatic cholangiocarcinoma: a possible role of hepatitis B virus.
  • There are several established risk factors for intrahepatic cholangiocarcinoma (ICC), namely primary sclerosing cholangitis, fibropolycystic liver disease, parasitic infection, intrahepatic biliary stones and chemical carcinogen exposure.
  • [MeSH-major] Cholangiocarcinoma / epidemiology. Hepatitis B, Chronic / complications. Liver Neoplasms / epidemiology
  • [MeSH-minor] Adult. Alanine Transaminase / blood. Blood Donors. Cohort Studies. Female. Hepacivirus / pathogenicity. Humans. Japan. Male. Middle Aged. Retrospective Studies. Risk Factors

  • Genetic Alliance. consumer health - Hepatitis.
  • Genetic Alliance. consumer health - Intrahepatic cholangiocarcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2009 Blackwell Publishing Ltd.
  • [Cites] Lancet. 2005 Oct 8;366(9493):1303-14 [16214602.001]
  • [Cites] Asian Pac J Cancer Prev. 2005 Jul-Sep;6(3):244-50 [16235981.001]
  • [Cites] Hum Pathol. 2006 Sep;37(9):1211-6 [16938527.001]
  • [Cites] Am J Gastroenterol. 2007 May;102(5):1016-21 [17324130.001]
  • [Cites] Clin Gastroenterol Hepatol. 2007 Oct;5(10):1221-8 [17689296.001]
  • [Cites] World J Gastroenterol. 2008 Jan 28;14(4):632-5 [18203300.001]
  • [Cites] Hepatology. 2008 Jul;48(1):308-21 [18536057.001]
  • [Cites] Am J Gastroenterol. 2008 Jul;103(7):1716-20 [18557716.001]
  • [Cites] Hepatology. 2009 Jan;49(1):116-23 [19085911.001]
  • [Cites] Br J Cancer. 2009 Jun 2;100(11):1765-70 [19436294.001]
  • [Cites] Cancer. 2000 Jun 1;88(11):2471-7 [10861422.001]
  • [Cites] Cancer Causes Control. 2001 Dec;12(10):959-64 [11808716.001]
  • [Cites] Semin Liver Dis. 2004 May;24(2):115-25 [15192785.001]
  • [Cites] Cancer Sci. 2004 Jul;95(7):592-5 [15245596.001]
  • [Cites] World J Gastroenterol. 2004 Aug 1;10(15):2259-62 [15259077.001]
  • [Cites] Int J Cancer. 2004 Dec 20;112(6):1075-80 [15386355.001]
  • [Cites] Cancer. 1980 May 15;45(10):2663-9 [6155197.001]
  • [Cites] Vox Sang. 1993;65(3):199-203 [7504373.001]
  • [Cites] Nihon Shokakibyo Gakkai Zasshi. 1994 Feb;91(2):154-61 [8114321.001]
  • [Cites] Semin Liver Dis. 1994 May;14(2):109-14 [8047893.001]
  • [Cites] Mayo Clin Proc. 1995 May;70(5):425-9 [7537346.001]
  • [Cites] Int J Epidemiol. 1996 Oct;25(5):933-40 [8921477.001]
  • [Cites] J Epidemiol. 1998 Dec;8(5):292-6 [9884479.001]
  • [Cites] Gastroenterology. 2005 Mar;128(3):620-6 [15765398.001]
  • (PMID = 20002305.001).
  • [ISSN] 1365-2893
  • [Journal-full-title] Journal of viral hepatitis
  • [ISO-abbreviation] J. Viral Hepat.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] EC 2.6.1.2 / Alanine Transaminase
  • [Other-IDs] NLM/ PMC3020326
  •  go-up   go-down


80. Corvera CU, Blumgart LH, Darvishian F, Klimstra DS, DeMatteo R, Fong Y, D'Angelica M, Jarnagin WR: Clinical and pathologic features of proximal biliary strictures masquerading as hilar cholangiocarcinoma. J Am Coll Surg; 2005 Dec;201(6):862-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical and pathologic features of proximal biliary strictures masquerading as hilar cholangiocarcinoma.
  • Histologic reexamination identified five different benign processes: lymphoplasmacytic sclerosing pancreatitis and cholangitis, primary sclerosing cholangitis, granulomatous disease, nonspecific fibrosis/inflammation, and stone disease.
  • [MeSH-major] Bile Duct Neoplasms / diagnosis. Bile Ducts, Intrahepatic / pathology. Cholangiocarcinoma / diagnosis. Cholestasis, Extrahepatic / etiology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Constriction, Pathologic. Diagnosis, Differential. Female. Humans. Male. Middle Aged. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16310689.001).
  • [ISSN] 1072-7515
  • [Journal-full-title] Journal of the American College of Surgeons
  • [ISO-abbreviation] J. Am. Coll. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


81. Slupski MW, Szczylik C, Jasinski MK: Unexpected response to systemic chemotherapy in case of primarily nonresectable advanced disseminated intrahepatic cholangiocarcinoma. World J Surg Oncol; 2007;5:36
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Unexpected response to systemic chemotherapy in case of primarily nonresectable advanced disseminated intrahepatic cholangiocarcinoma.
  • BACKGROUND: Cholangiocellular cancers account for about 10-15% of primary liver cancers.
  • CASE PRESENTATION: The case described shows remission of a disseminated cholangiocellular carcinoma (focal changes in liver, metastases to lungs) after neoadjuvant chemotherapy.
  • Tumour biopsy and histopathological examination revealed cholangiocellular carcinoma.
  • The histopathological examination did not reveal any viable carcinoma cells, only necrotic tissues in place of the primary tumour as well as in local portal vein branches was seen.
  • CONCLUSION: Appropriate neoadjuvant chemotherapy may allow radical resection in a previously unresectable cholangiocellular cancer.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bile Duct Neoplasms / drug therapy. Bile Ducts, Intrahepatic. Cholangiocarcinoma / drug therapy
  • [MeSH-minor] Adult. Cisplatin / administration & dosage. Doxorubicin / administration & dosage. Fluorouracil / administration & dosage. Humans. Interferon-alpha / administration & dosage. Male. Neoadjuvant Therapy. Recombinant Proteins

  • Genetic Alliance. consumer health - Intrahepatic cholangiocarcinoma.
  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Surg. 2000 Sep;87(9):1182-7 [10971425.001]
  • [Cites] Braz J Med Biol Res. 2004 Nov;37(11):1689-705 [15517086.001]
  • [Cites] Ann Oncol. 2002 Aug;13(8):1192-6 [12181241.001]
  • [Cites] Gut. 2002 Nov;51 Suppl 6:VI1-9 [12376491.001]
  • [Cites] Semin Oncol. 2002 Dec;29(6 Suppl 20):40-5 [12577232.001]
  • [Cites] Ann Oncol. 2004 May;15(5):770-4 [15111345.001]
  • [Cites] Hepatobiliary Pancreat Dis Int. 2004 May;3(2):279-83 [15138126.001]
  • [Cites] J Clin Oncol. 1984 Nov;2(11):1245-8 [6092556.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1993 Nov-Dec;2(6):537-44 [8268770.001]
  • [Cites] World J Surg. 1995 Jan-Feb;19(1):83-8 [7740815.001]
  • [Cites] J Clin Oncol. 1996 Aug;14(8):2311-5 [8708722.001]
  • [Cites] Ann Oncol. 1998 Jun;9(6):653-6 [9681080.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 1998;5(1):41-7 [9683753.001]
  • [Cites] Oncology. 1999 Apr;56(3):177-80 [10202270.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 1999;6(2):122-7 [10398898.001]
  • [Cites] Semin Liver Dis. 1999;19(3):271-85 [10518307.001]
  • [Cites] Clin Cancer Res. 2001 Nov;7(11):3375-80 [11705850.001]
  • (PMID = 17376238.001).
  • [ISSN] 1477-7819
  • [Journal-full-title] World journal of surgical oncology
  • [ISO-abbreviation] World J Surg Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Interferon-alpha; 0 / Recombinant Proteins; 80168379AG / Doxorubicin; 99210-65-8 / interferon alfa-2b; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil; PIAF regimen
  • [Other-IDs] NLM/ PMC1839091
  • [General-notes] NLM/ Original DateCompleted: 20070726
  •  go-up   go-down


82. Chen C, Huang M, Yang J, Yang C, Yeh Y, Wu H, Chou D, Yueh S, Nien C: Reappraisal of percutaneous transhepatic cholangioscopic lithotomy for primary hepatolithiasis. Surg Endosc; 2005 Apr;19(4):505-9
MedlinePlus Health Information. consumer health - Liver Diseases.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Reappraisal of percutaneous transhepatic cholangioscopic lithotomy for primary hepatolithiasis.
  • Patients showing the coexistence of retained or recurrent hepatolithiasis demonstrated a higher incidence of recurrent cholangitis (57% [13/23] vs 14% [7/51]; p < 0.01) or cholangiocarcinoma (17% [4/23]) vs 0% [0/51]; p < 0.01).
  • CONCLUSIONS: The findings show that PTCSL is effective for treating primary hepatolithiasis, and that complete stone clearance is mandatory to diminish the sequelae of hepatolithiasis.
  • [MeSH-minor] Adult. Aged. Cholangiocarcinoma / epidemiology. Cholangitis / epidemiology. Cholelithiasis / epidemiology. Comorbidity. Constriction, Pathologic / epidemiology. Female. Follow-Up Studies. Gallbladder Neoplasms / epidemiology. Hepatectomy. Hepatic Duct, Common / pathology. Humans. Lithotripsy. Liver Abscess / epidemiology. Male. Middle Aged. Postoperative Complications / epidemiology. Recurrence. Reoperation. Retrospective Studies. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15959714.001).
  • [ISSN] 1432-2218
  • [Journal-full-title] Surgical endoscopy
  • [ISO-abbreviation] Surg Endosc
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


83. Talwalkar JA, Lindor KD: Primary sclerosing cholangitis. Inflamm Bowel Dis; 2005 Jan;11(1):62-72
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary sclerosing cholangitis.
  • Primary sclerosing cholangitis (PSC) is a chronic cholestatic liver disease characterized by inflammation and fibrosis of the intra- and extrahepatic bile ducts.
  • Important complications from PSC include metabolic bone disease, colorectal neoplasia, and cholangiocarcinoma.
  • [MeSH-minor] Adult. Biopsy. Cholangiography. Diagnosis, Differential. Female. Humans. Incidence. Liver Transplantation. Male. Pregnancy. Pregnancy Complications. Prognosis. Risk Factors

  • Genetic Alliance. consumer health - Primary sclerosing cholangitis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15674115.001).
  • [ISSN] 1078-0998
  • [Journal-full-title] Inflammatory bowel diseases
  • [ISO-abbreviation] Inflamm. Bowel Dis.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 198
  •  go-up   go-down


84. Sawanyawisuth K, Wongkham C, Pairojkul C, Saeseow OT, Riggins GJ, Araki N, Wongkham S: Methionine aminopeptidase 2 over-expressed in cholangiocarcinoma: potential for drug target. Acta Oncol; 2007;46(3):378-85
MedlinePlus Health Information. consumer health - Bile Duct Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Methionine aminopeptidase 2 over-expressed in cholangiocarcinoma: potential for drug target.
  • It was occasionally expressed with weak staining in normal bile duct epithelium but was strikingly over-expressed in dysplastic bile duct epithelia, primary and metastatic CCA tissues (p < 0.001).
  • All metastatic tumors had stronger expression of MetAP2 than the corresponding primary tumors.
  • [MeSH-major] Aminopeptidases / biosynthesis. Aminopeptidases / drug effects. Bile Duct Neoplasms / metabolism. Bile Ducts, Intrahepatic / enzymology. Bile Ducts, Intrahepatic / pathology. Cholangiocarcinoma / metabolism. Metalloendopeptidases / biosynthesis. Metalloendopeptidases / drug effects
  • [MeSH-minor] Adult. Aged. Angiogenesis Inhibitors / pharmacology. Biomarkers, Tumor / blood. Cell Line, Tumor. Cell Proliferation / drug effects. Cyclohexanes / pharmacology. Electrophoresis, Polyacrylamide Gel. Epithelium / drug effects. Epithelium / enzymology. Epithelium / pathology. Fatty Acids, Unsaturated / pharmacology. Female. Humans. Immunoblotting. Immunohistochemistry. Male. Middle Aged. Neoplasm Invasiveness. Sesquiterpenes / pharmacology. Up-Regulation / drug effects

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17450475.001).
  • [ISSN] 0284-186X
  • [Journal-full-title] Acta oncologica (Stockholm, Sweden)
  • [ISO-abbreviation] Acta Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Norway
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Biomarkers, Tumor; 0 / Cyclohexanes; 0 / Fatty Acids, Unsaturated; 0 / Sesquiterpenes; 7OW73204U1 / fumagillin; EC 3.4.11.- / Aminopeptidases; EC 3.4.11.18 / methionine aminopeptidase 2; EC 3.4.24.- / Metalloendopeptidases
  •  go-up   go-down


85. Homayounfar K, Gunawan B, Cameron S, Haller F, Baumhoer D, Uecker S, Sander B, Ramadori G, Lorf T, Füzesi L: Pattern of chromosomal aberrations in primary liver cancers identified by comparative genomic hybridization. Hum Pathol; 2009 Jun;40(6):834-42
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pattern of chromosomal aberrations in primary liver cancers identified by comparative genomic hybridization.
  • Little is known about the molecular cytogenetic changes in cholangiocarcinoma and combined hepatocellular-cholangiocarcinoma, and on the prognostic significance of chromosomal imbalances in hepatocellular carcinoma.
  • Seventy-eight cases of primary liver cancer with available median follow-up of 16.5 months, including 49 hepatocellular carcinomas, 22 cholangiocarcinomas, and 7 combined hepatocellular-cholangiocarcinomas, were examined by comparative genomic hybridization.
  • In hepatocellular carcinoma, the most frequent changes were +8q (54%), -8p (54%), and +1q (42%), followed by -6q (35%), -4q (33%), -13q (29%), -14q (25%), -16q (19%), -17p (19%), +17q (17%), and +20q (15%).
  • In comparison, cholangiocarcinoma had more gains, losses, and breakpoints than hepatocellular carcinoma or combined hepatocellular-cholangiocarcinoma, specifically more frequently -6q (91%), -3p (68%), -9p (55%), -14q (55%), -13q (45%), +1q (41%), +7q (36%), +7p (32%), and +8q (32%).
  • Combined losses at 6q and 3p appeared to be highly characteristic for cholangiocarcinoma.
  • In contrast, combined hepatocellular-cholangiocarcinoma shared frequent +1q (71%), +8q (57%), and -8p (57%) with hepatocellular carcinoma, but a tendency for higher numbers of imbalances with cholangiocarcinoma.
  • Cholangiocarcinoma is characterized by combined losses at 6q and 3p and a tendency for chromosomal instability.
  • On the other hand, combined hepatocellular-cholangiocarcinoma may share similar chromosomal changes with both hepatocellular carcinoma and cholangiocarcinoma, as reflected by common hepatocellular carcinoma-like +8q, +1q, and -8p and a tendency for cholangiocarcinoma-like chromosomal instability.
  • In hepatocellular carcinoma, higher number of gains may prove an adverse prognostic parameter.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Carcinoma, Hepatocellular / genetics. Carcinoma, Hepatocellular / pathology. Cholangiocarcinoma / genetics. Cholangiocarcinoma / pathology. Comparative Genomic Hybridization. Female. Humans. Male. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19200581.001).
  • [ISSN] 1532-8392
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


86. Clemente G, De Rose AM, Giordano M, Mele C, Vellone M, Ardito F, Murazio M, Giuliante F, Giovannini I, Nuzzo G: [Primary intrahepatic lithiasis: indications and results of liver resection]. Chir Ital; 2009 May-Jun;61(3):273-80
MedlinePlus Health Information. consumer health - Gallstones.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Primary intrahepatic lithiasis: indications and results of liver resection].
  • The aim of this study was to review a series of patients submitted to hepatectomy for primary intrahepatic lithiasis to evaluate early and late results with an assessment of indications, methods and long-term outcomes.
  • From January 1992 to December 2007, 40 patients (25 males and 15 females with a mean age of 51 years) underwent surgery for primary intrahepatic lithiasis in our Hepato-biliary Surgery Unit.
  • A cholangiocarcinoma was found in 4 patients (10%) and only two of these underwent liver resection, while an exploratory laparotomy was performed in the remaining two patients for an unresectable tumour, unexpected before surgery.
  • Primary intrahepatic lithiasis is diagnosed increasingly in Western countries as a result of the improvement in imaging techniques.
  • Biliary pain and cholangitis are the most common presenting symptoms, whereas cholangiocarcinoma represents the unfavourable complication of the disease.
  • [MeSH-minor] Adult. Aged. Bile Duct Neoplasms / surgery. Bile Ducts, Intrahepatic / surgery. Cholangiocarcinoma / surgery. Cholestasis, Intrahepatic / surgery. Female. Follow-Up Studies. Humans. Male. Middle Aged. Retrospective Studies. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19694228.001).
  • [ISSN] 0009-4773
  • [Journal-full-title] Chirurgia italiana
  • [ISO-abbreviation] Chir Ital
  • [Language] ita
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


87. Petrowsky H, Wildbrett P, Husarik DB, Hany TF, Tam S, Jochum W, Clavien PA: Impact of integrated positron emission tomography and computed tomography on staging and management of gallbladder cancer and cholangiocarcinoma. J Hepatol; 2006 Jul;45(1):43-50
MedlinePlus Health Information. consumer health - Gallbladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Impact of integrated positron emission tomography and computed tomography on staging and management of gallbladder cancer and cholangiocarcinoma.
  • PET/CT and ceCT provided a comparable accuracy for the primary intra- (n=14) and extra-hepatic cholangiocarcinomas (n=33).
  • [MeSH-major] Bile Duct Neoplasms / pathology. Bile Ducts, Extrahepatic. Bile Ducts, Intrahepatic. Cholangiocarcinoma / pathology. Gallbladder Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Neoplasm Staging. Positron-Emission Tomography. Recurrence. Reproducibility of Results. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16690156.001).
  • [ISSN] 0168-8278
  • [Journal-full-title] Journal of hepatology
  • [ISO-abbreviation] J. Hepatol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  •  go-up   go-down


88. Shinohara ET, Mitra N, Guo M, Metz JM: Radiation therapy is associated with improved survival in the adjuvant and definitive treatment of intrahepatic cholangiocarcinoma. Int J Radiat Oncol Biol Phys; 2008 Dec 1;72(5):1495-501
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radiation therapy is associated with improved survival in the adjuvant and definitive treatment of intrahepatic cholangiocarcinoma.
  • The primary endpoint was overall survival (OS).
  • [MeSH-major] Bile Duct Neoplasms / radiotherapy. Cholangiocarcinoma / radiotherapy. Liver Neoplasms / radiotherapy
  • [MeSH-minor] Adult. African Continental Ancestry Group. Aged. Aged, 80 and over. European Continental Ancestry Group. Female. Humans. Male. Middle Aged. Neoplasm Staging. Radiotherapy, Adjuvant. Retrospective Studies. Survival Analysis. Survivors. Young Adult

  • Genetic Alliance. consumer health - Intrahepatic cholangiocarcinoma.
  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18472359.001).
  • [ISSN] 1879-355X
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Grant] United States / PHS HHS / / P30-CAO16520
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


89. Tischendorf JJ, Krüger M, Trautwein C, Duckstein N, Schneider A, Manns MP, Meier PN: Cholangioscopic characterization of dominant bile duct stenoses in patients with primary sclerosing cholangitis. Endoscopy; 2006 Jul;38(7):665-9
Genetic Alliance. consumer health - Primary sclerosing cholangitis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cholangioscopic characterization of dominant bile duct stenoses in patients with primary sclerosing cholangitis.
  • BACKGROUND AND STUDY AIMS: Primary sclerosing cholangitis (PSC) is associated with the development of cholangiocarcinoma in up to 10 % of patients.
  • Cholangiography or endoscopic tissue sampling does not reliably distinguish between cholangiocarcinoma and a benign dominant bile duct stenosis.
  • RESULTS: Twelve PSC patients (23 %) had dominant bile duct stenoses caused by cholangiocarcinoma, whereas 41 of the 53 patients (77 %) had benign dominant bile duct stenoses.
  • [MeSH-minor] Adolescent. Adult. Aged. Bile Duct Neoplasms / chemically induced. Bile Duct Neoplasms / complications. Bile Duct Neoplasms / pathology. Bile Ducts, Intrahepatic. Cholangiocarcinoma / complications. Cholangiocarcinoma / diagnosis. Cholangiocarcinoma / pathology. Cholangiopancreatography, Endoscopic Retrograde. Cholestasis / etiology. Constriction, Pathologic. Cytodiagnosis. Diagnosis, Differential. Female. Humans. Male. Middle Aged. Predictive Value of Tests. Sensitivity and Specificity

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Endoscopy. 2006 Jul;38(7):743-4 [16810598.001]
  • [ErratumIn] Endoscopy. 2006 Aug;38(8):852
  • (PMID = 16673310.001).
  • [ISSN] 0013-726X
  • [Journal-full-title] Endoscopy
  • [ISO-abbreviation] Endoscopy
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


90. Claessen MM, Vleggaar FP, Tytgat KM, Siersema PD, van Buuren HR: High lifetime risk of cancer in primary sclerosing cholangitis. J Hepatol; 2009 Jan;50(1):158-64
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High lifetime risk of cancer in primary sclerosing cholangitis.
  • BACKGROUND/AIMS: Primary sclerosing cholangitis (PSC) patients are at risk for developing cholangiocarcinoma (CCA) and colorectal carcinoma (CRC).
  • [MeSH-major] Bile Duct Neoplasms / epidemiology. Bile Ducts, Intrahepatic. Cholangiocarcinoma / embryology. Cholangitis, Sclerosing / complications. Colorectal Neoplasms / epidemiology
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Female. Follow-Up Studies. Humans. Inflammatory Bowel Diseases / complications. Kaplan-Meier Estimate. Longitudinal Studies. Male. Middle Aged. Proportional Hazards Models. Retrospective Studies. Risk Factors. Young Adult

  • Genetic Alliance. consumer health - Primary sclerosing cholangitis.
  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19012991.001).
  • [ISSN] 0168-8278
  • [Journal-full-title] Journal of hepatology
  • [ISO-abbreviation] J. Hepatol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] England
  •  go-up   go-down


91. Tanaka A, Takamori Y, Toda G, Ohnishi S, Takikawa H: Outcome and prognostic factors of 391 Japanese patients with primary sclerosing cholangitis. Liver Int; 2008 Aug;28(7):983-9
Genetic Alliance. consumer health - Primary sclerosing cholangitis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcome and prognostic factors of 391 Japanese patients with primary sclerosing cholangitis.
  • OBJECTIVES: We performed a national survey in 2003, and demonstrated characteristic features of primary sclerosing cholangitis (PSC) patients in Japan.
  • Cholangiocarcinoma (CCA) was found in 14 (3.6%) patients, and only two out of 125 PSC patients exhibited a history of inflammatory bowel diseases.
  • [MeSH-minor] Adult. Aged. Bile Duct Neoplasms / mortality. Bile Duct Neoplasms / pathology. Bile Ducts, Intrahepatic / pathology. Cholangiocarcinoma / mortality. Cholangiocarcinoma / pathology. Comorbidity. Female. Follow-Up Studies. Humans. Japan / epidemiology. Liver Transplantation. Male. Middle Aged. Prognosis. Surveys and Questionnaires. Survival Rate. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18397233.001).
  • [ISSN] 1478-3231
  • [Journal-full-title] Liver international : official journal of the International Association for the Study of the Liver
  • [ISO-abbreviation] Liver Int.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


92. Awadallah NS, Chen YK, Piraka C, Antillon MR, Shah RJ: Is there a role for cholangioscopy in patients with primary sclerosing cholangitis? Am J Gastroenterol; 2006 Feb;101(2):284-91
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Is there a role for cholangioscopy in patients with primary sclerosing cholangitis?
  • OBJECTIVES: Assess the role of cholangioscopy in primary sclerosing cholangitis for 1) detection of cholangiocarcinoma using cholangioscopy-assisted biopsy 2) detection of stones not seen on cholangiography 3) stone removal with cholangioscopy-directed lithotripsy.
  • HISTOLOGY: positive for extrahepatic cholangiocarcinoma (N = 1), negative/atypical (N = 31), and inadequate (N = 1).
  • Eight patients have undergone transplant and cholangiocarcinoma was present in the explant of two at 1 and 12 months post-cholangioscopy, respectively.
  • CONCLUSIONS: This is the first series of patients with primary sclerosing cholangitis undergoing cholangioscopy for the evaluation of dominant strictures and cholangioscopy-directed stone therapy with demonstrable clinical benefits.
  • Despite the use of cholangioscopy, diagnosis of cholangiocarcinoma remains technically challenging.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Bile Duct Neoplasms / diagnosis. Biopsy. Cholangiocarcinoma / diagnosis. Cholelithiasis / diagnosis. Diagnosis, Differential. Female. Follow-Up Studies. Humans. Male. Middle Aged. Prospective Studies

  • Genetic Alliance. consumer health - Primary sclerosing cholangitis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16454832.001).
  • [ISSN] 0002-9270
  • [Journal-full-title] The American journal of gastroenterology
  • [ISO-abbreviation] Am. J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


93. Weber C, Kuhlencordt R, Grotelueschen R, Wedegaertner U, Ang TL, Adam G, Soehendra N, Seitz U: Magnetic resonance cholangiopancreatography in the diagnosis of primary sclerosing cholangitis. Endoscopy; 2008 Sep;40(9):739-45
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Magnetic resonance cholangiopancreatography in the diagnosis of primary sclerosing cholangitis.
  • BACKGROUND AND STUDY AIMS: Magnetic resonance cholangiopancreatography (MRCP) is a less-invasive alternative to endoscopic retrograde cholangiopancreatography (ERCP) for the diagnosis of primary sclerosing cholangitis (PSC).
  • CONCLUSIONS: MRCP can diagnose PSC but has difficulties in early PSC and in cirrhosis, and in the differentiation of cholangiocarcinoma, Caroli's disease, and secondary sclerosing cholangitis.
  • [MeSH-minor] Adolescent. Adult. Aged. Bile Duct Neoplasms / diagnosis. Caroli Disease / diagnosis. Cholangiocarcinoma / diagnosis. Cholangiopancreatography, Endoscopic Retrograde / adverse effects. Diagnosis, Differential. Diagnostic Errors. False Positive Reactions. Female. Humans. Image Enhancement / methods. Liver Cirrhosis / diagnosis. Male. Middle Aged. Observer Variation. Pancreatic Pseudocyst / etiology. Pancreatitis / etiology. Retrospective Studies. Sensitivity and Specificity

  • Genetic Alliance. consumer health - Primary sclerosing cholangitis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18698533.001).
  • [ISSN] 1438-8812
  • [Journal-full-title] Endoscopy
  • [ISO-abbreviation] Endoscopy
  • [Language] eng
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


94. Ataseven H, Parlak E, Yüksel I, Başar O, Ertuğrul I, Saşmaz N, Sahin B: Primary sclerosing cholangitis in Turkish patients: characteristic features and prognosis. Hepatobiliary Pancreat Dis Int; 2009 Jun;8(3):312-5
Genetic Alliance. consumer health - Primary sclerosing cholangitis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary sclerosing cholangitis in Turkish patients: characteristic features and prognosis.
  • BACKGROUND: Primary sclerosing cholangitis (PSC) is a chronic cholestatic liver disease characterized by destruction and fibrosis of the bile ducts.
  • Cholangiocarcinoma was found in 2 (5.7%) of the patients and cirrhosis was detected in 7 (20%); 5 (14.3%) underwent liver transplantation.
  • [MeSH-minor] Acute Disease. Adolescent. Adult. Aged. Aged, 80 and over. Bile Duct Neoplasms / etiology. Bile Ducts, Intrahepatic. Cholangiocarcinoma / etiology. Cholangiopancreatography, Endoscopic Retrograde. Cholestasis / etiology. Female. Follow-Up Studies. Humans. Inflammatory Bowel Diseases / etiology. Liver Cirrhosis / etiology. Liver Transplantation. Male. Middle Aged. Prognosis. Prospective Studies. Stents. Turkey. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19502174.001).
  • [ISSN] 1499-3872
  • [Journal-full-title] Hepatobiliary & pancreatic diseases international : HBPD INT
  • [ISO-abbreviation] HBPD INT
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  •  go-up   go-down


95. Bangarulingam SY, Bjornsson E, Enders F, Barr Fritcher EG, Gores G, Halling KC, Lindor KD: Long-term outcomes of positive fluorescence in situ hybridization tests in primary sclerosing cholangitis. Hepatology; 2010 Jan;51(1):174-80
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term outcomes of positive fluorescence in situ hybridization tests in primary sclerosing cholangitis.
  • Patients with primary sclerosing cholangitis (PSC) are at increased risk for developing cholangiocarcinoma (CCA).
  • [MeSH-major] Cholangiocarcinoma / diagnosis. Cholangiocarcinoma / etiology. Cholangitis, Sclerosing / complications. Cholangitis, Sclerosing / diagnosis
  • [MeSH-minor] Adult. Aneuploidy. Female. Humans. In Situ Hybridization, Fluorescence. Kaplan-Meier Estimate. Liver Transplantation. Male. Middle Aged

  • Genetic Alliance. consumer health - Primary sclerosing cholangitis.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Hepatology. 2010 Jul;52(1):393-4; author reply 394-5 [20583197.001]
  • [CommentIn] Hepatology. 2010 Jan;51(1):16-9 [20034029.001]
  • (PMID = 19877179.001).
  • [ISSN] 1527-3350
  • [Journal-full-title] Hepatology (Baltimore, Md.)
  • [ISO-abbreviation] Hepatology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


96. Lin ZY, Chuang WL, Chuang YH, Yu ML, Hsieh MY, Wang LY, Tsai JF: Discordant influence of amphotericin B on epirubicin cytotoxicity in primary hepatic malignant cells collected by a new primary culture technique. J Gastroenterol Hepatol; 2006 Feb;21(2):398-405
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Discordant influence of amphotericin B on epirubicin cytotoxicity in primary hepatic malignant cells collected by a new primary culture technique.
  • BACKGROUND: The purpose of this prospective study was to investigate whether amphotericin B (AmB) had any potential role in the systemic chemotherapy of primary hepatic malignancy using cancer cells collected by the authors' method of primary culture.
  • METHODS: The specimens obtained by ultrasound-guided fine-needle aspiration biopsy (22 G) from 15 patients with hepatocellular carcinoma (HCC) and one with cholangiocarcinoma were plated into culture flask without disaggregation by trypsin-ethylenediamine tetra-acetic acid solution.
  • Six patients with HCC and one patient with cholangiocarcinoma (7/16, 44%) had successful culture and the cancer cells at the 4th passage were continuously exposed to therapeutic ranges of epirubicin (0, 0.5, 1.0, 1.5, 2.0 microg/mL) with or without the combination of 2.5 microg/mL AmB for 24 h. 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay was applied to evaluate the effects of the drugs.
  • RESULTS: Addition of AmB showed no influence on epirubicin cytotoxicity in two patients (one partial resistant HCC and one epirubicin-sensitive cholangiocarcinoma; 25%), augmentation of the epirubicin cytotoxicity in two patients (one total resistant HCC, partial resistant HA 22T/VGH cell line and one epirubicin-sensitive HCC; 37.5%), and decrease of epirubicin cytotoxicity in the remaining three (one partial resistant and two epirubicin-sensitive HCC; 37.5%).
  • CONCLUSIONS: Amphotericin B has a discordant influence on epirubicin cytotoxicity in primary cultured hepatic malignant cells.
  • Application of AmB in the systemic chemotherapy of primary hepatic malignancy should be limited to patients with positive AmB effect evaluated by an in vitro sensitivity test such as the present method.
  • [MeSH-minor] Adult. Aged. Bile Duct Neoplasms / drug therapy. Bile Duct Neoplasms / pathology. Bile Ducts, Intrahepatic. Biopsy, Fine-Needle. Carcinoma, Hepatocellular / drug therapy. Carcinoma, Hepatocellular / pathology. Cell Culture Techniques. Cell Proliferation / drug effects. Cholangiocarcinoma / drug therapy. Cholangiocarcinoma / pathology. Drug Interactions. Drug Therapy, Combination. Female. Follow-Up Studies. Humans. Male. Middle Aged. Prospective Studies. Treatment Outcome. Tumor Cells, Cultured

  • MedlinePlus Health Information. consumer health - Antibiotics.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. AMPHOTERICIN B .
  • Hazardous Substances Data Bank. EPIRUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16509865.001).
  • [ISSN] 0815-9319
  • [Journal-full-title] Journal of gastroenterology and hepatology
  • [ISO-abbreviation] J. Gastroenterol. Hepatol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents; 0 / Antibiotics, Antineoplastic; 3Z8479ZZ5X / Epirubicin; 7XU7A7DROE / Amphotericin B
  •  go-up   go-down


97. Bergquist A, Said K, Broomé U: Changes over a 20-year period in the clinical presentation of primary sclerosing cholangitis in Sweden. Scand J Gastroenterol; 2007 Jan;42(1):88-93
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Changes over a 20-year period in the clinical presentation of primary sclerosing cholangitis in Sweden.
  • OBJECTIVE: The use of magnetic resonance cholangiopancreaticography (MRCP) as a non-invasive diagnostic tool for primary sclerosing cholangitis (PSC), together with increased clinical awareness of the disease, has led to earlier diagnosis.
  • The aim of this study was to investigate the clinical presentation of PSC including its association with inflammatory bowel disease (IBD) and the development of cholangiocarcinoma at one centre over an observation period of 20 years.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Bile Duct Neoplasms / complications. Bile Ducts, Intrahepatic. Cholangiocarcinoma / complications. Cholangiopancreatography, Endoscopic Retrograde. Cholangiopancreatography, Magnetic Resonance. Female. Humans. Inflammatory Bowel Diseases / complications. Male. Sweden

  • Genetic Alliance. consumer health - Primary sclerosing cholangitis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17190768.001).
  • [ISSN] 0036-5521
  • [Journal-full-title] Scandinavian journal of gastroenterology
  • [ISO-abbreviation] Scand. J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Norway
  •  go-up   go-down


98. Pawlik TM, Olbrecht VA, Pitt HA, Gleisner AL, Choti MA, Schulick RD, Cameron JL: Primary sclerosing cholangitis: role of extrahepatic biliary resection. J Am Coll Surg; 2008 May;206(5):822-30; discussion 830-2
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary sclerosing cholangitis: role of extrahepatic biliary resection.
  • BACKGROUND: Most centers advocate orthotopic liver transplantation (OLT) for patients with primary sclerosing cholangitis (PSC) and cirrhosis.
  • Cholangiocarcinoma did not develop in any patients, and only seven required OLT.
  • [MeSH-minor] Adult. Female. Follow-Up Studies. Humans. Liver Cirrhosis / etiology. Liver Transplantation. Male. Middle Aged. Morbidity. Survival Analysis

  • Genetic Alliance. consumer health - Primary sclerosing cholangitis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18471705.001).
  • [ISSN] 1879-1190
  • [Journal-full-title] Journal of the American College of Surgeons
  • [ISO-abbreviation] J. Am. Coll. Surg.
  • [Language] eng
  • [Grant] United States / NCRR NIH HHS / RR / 1KL2RR025006-01
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


99. Malouf G, Falissard B, Azoulay D, Callea F, Ferrell LD, Goodman ZD, Hayashi Y, Hsu HC, Hubscher SG, Kojiro M, Ng IO, Paterson AC, Reynes M, Zafrani ES, Emile JF: Is histological diagnosis of primary liver carcinomas with fibrous stroma reproducible among experts? J Clin Pathol; 2009 Jun;62(6):519-24
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Is histological diagnosis of primary liver carcinomas with fibrous stroma reproducible among experts?
  • Little is known about the reproducibility of the pathological diagnosis of primary liver carcinomas.
  • Therefore, this study aimed to evaluate the worldwide variation in the pathological expert diagnoses of primary liver carcinomas with fibrous stroma in patients who did not have cirrhosis.
  • RESULTS: The interobserver reproducibility for diagnosis of hepatocellular carcinoma subtypes and cholangiocarcinomas was poor (kappa 0.23-0.52), even when the experts considered that the diagnosis required no additional stains or clinical information.
  • Interestingly, multidimensional scaling revealed three main clusters of tumours: hepatocellular carcinoma with no other specifications (n = 13), fibrolamellar hepatocellular carcinoma (n = 3) and cholangiocarcinoma (n = 9).
  • CONCLUSIONS: The results demonstrate the poor reproducibility among experts of the pathological diagnosis of primary liver carcinomas with fibrous stroma in patients who did not have cirrhosis, and highlight that the systematic use of immunohistochemistry may improve the diagnostic accuracy.
  • [MeSH-major] Carcinoma, Hepatocellular / pathology. Cholangiocarcinoma / pathology. Liver Neoplasms / pathology. Medical Oncology / standards
  • [MeSH-minor] Adolescent. Adult. Aged. Antibodies / analysis. Biomarkers, Tumor / analysis. Carcinoembryonic Antigen / immunology. Child. Cluster Analysis. Diagnosis, Differential. Female. Hepatocytes / pathology. Humans. Immunohistochemistry. Keratin-19 / immunology. Keratin-7 / immunology. Keratins / analysis. Male. Middle Aged. Reproducibility of Results. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19155239.001).
  • [ISSN] 1472-4146
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies; 0 / Biomarkers, Tumor; 0 / Carcinoembryonic Antigen; 0 / Keratin-19; 0 / Keratin-7; 68238-35-7 / Keratins
  •  go-up   go-down


100. Layfield LJ, Cramer H: Primary sclerosing cholangitis as a cause of false positive bile duct brushing cytology: report of two cases. Diagn Cytopathol; 2005 Feb;32(2):119-24
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary sclerosing cholangitis as a cause of false positive bile duct brushing cytology: report of two cases.
  • Primary sclerosing cholangitis (PSC) is a chronic cholestatic liver disease of unknown etiology characterized by ongoing inflammation, destruction, and fibrosis of intrahepatic and extrahepatic bile ducts.
  • Malignant degeneration resulting in cholangiocarcinoma is a well-recognized sequela of PSC.
  • Bile duct brushing cytology is the primary screening technique for cholangiocarcinoma.
  • We report two patients with PSC in whom bile duct brush cytologies were falsely positive for carcinoma.
  • [MeSH-minor] Adult. Bile Duct Neoplasms / diagnosis. Bile Duct Neoplasms / pathology. Cholangiocarcinoma / diagnosis. Cholangiocarcinoma / pathology. False Positive Reactions. Female. Humans. Male. Middle Aged

  • Genetic Alliance. consumer health - Primary sclerosing cholangitis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2005 Wiley-Liss, Inc.
  • (PMID = 15637668.001).
  • [ISSN] 8755-1039
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down






Advertisement